Methusalem Report 2008 2009 - Universiteit Hasselt · 2011. 5. 19. · - Methusalem Report 2008-2009 - 9 HASSELT UNIVERSITY Methusalem Team leader: Prof. Dr. Geert Molenberghs Research

Methusalem Report 2008‐2009

University of Antwerp Centre of Excellence: Vaccine & Infectious Disease Institute VAXINFECTIO

Hasselt University Center for Statistics CenStat

- Table of Contents -

2

- Methusalem Report 2008-2009 -

3

Table of Contents

1 Methusalem Consortium ............................................................................................................................. 7

1.1 Composition of the Methusalem Consortium ...................................................................................... 7

1.2 Management structure of the Methusalem Consortium ..................................................................... 9

1.3 The Methusalem Consortium within the University of Antwerp & Hasselt University ......................... 9

Change in departmental structure of the Faculty of Medicine (UA) ............................................................ 9

Facilities (UA) ............................................................................................................................................ 10

Facilities (UHasselt) ................................................................................................................................... 10

2 Objectives of the Methusalem Consortium ............................................................................................... 11

3 Research Activities 2008‐2009 .................................................................................................................. 13

4 Dissemination Activities ............................................................................................................................ 17

4.1 Scientific papers in peer reviewed journals ....................................................................................... 17

4.2 Yearbooks .......................................................................................................................................... 17

4.3 Workshops/Conferences/summer course ......................................................................................... 18

Methusalem Research Days ...................................................................................................................... 18

Valentijn Vaccinatiesymposium ................................................................................................................. 18

Scientific Chair in Evidence Based Vaccinology .......................................................................................... 18

ESAC Meetings .......................................................................................................................................... 19

GRACE Meetings/workshops ..................................................................................................................... 20

VHPB Meetings ......................................................................................................................................... 21

Summer Course in Vaccinology ................................................................................................................. 22

AUHA Research Days ................................................................................................................................. 24

4.4 Intellectual property rights ................................................................................................................ 24

5 Communication ......................................................................................................................................... 25

5.1 Press releases .................................................................................................................................... 25

5.2 Website ............................................................................................................................................. 25

5.3 Newsletters ....................................................................................................................................... 26

6 International and National Collaborations................................................................................................. 29

6.1 Strategic collaborations with other research groups & industry ........................................................ 29

National Collaborations ............................................................................................................................. 29

- Table of Contents -

4

International Collaborations ...................................................................................................................... 31

6.2 Ad hoc collaboration with industry .................................................................................................... 37

7 External Research Funding ........................................................................................................................ 39

7.1 Overview of submitted projects 2008‐2009 ....................................................................................... 39

7.2 Overview of granted projects 2008‐2009 .......................................................................................... 41

7.3 Project proposals in the pipeline 2010‐2011 ..................................................................................... 57

7.4 Difficulties encountered with obtaining additional funding ............................................................... 57

8 Human Resources ..................................................................................................................................... 59

8.1 Overview of Methusalem Personnel .................................................................................................. 59

8.2 Opportunities for Postdoctoral Researchers ...................................................................................... 60

8.3 PhD students & PhDs obtained .......................................................................................................... 61

9 Budget & Investments ............................................................................................................................... 63

9.1 Overall budget 2008‐2014 ................................................................................................................. 63

9.2 Budget Vaxinfectio ............................................................................................................................ 63

Investments in expert personnel 2008‐2009 ............................................................................................. 63

Investments in state‐of‐the‐art technologies, methodologies and equipment 2008‐2009 ........................ 63

Future Investments in state‐of‐the‐art technologies, methodologies and equipment ............................... 65

9.3 Budget CenStat .................................................................................................................................. 65

Investments in expert personnel 2008‐2009 ............................................................................................. 65

Future Investments ................................................................................................................................... 65

10 Annexes .................................................................................................................................................... 67

10.1 ANNEX I: Administrative Information ................................................................................................ 69

10.2 ANNEX II: List of Papers, Books and Book chapters ............................................................................ 71

10.3 ANNEX III: Programmes of the Methusalem Research Days .............................................................. 81

Methusalem Research Day n°1 (2008) ...................................................................................................... 81

Methusalem Research Day n°2 (2009) ...................................................................................................... 83

10.4 ANNEX IV: Extracts of the Flemish Government Directive ................................................................. 85

10.5 ANNEX V: Personnel list anno 2009 ................................................................................................... 93


5

Methusalem Key Features Strengths

Multidisciplinary Consortium Vaxinfectio = Center of Excellence & in the process of becoming WHO Collaborating Center Employing 121 staff members of which 58 PhD students Over 120 papers published for the period 2008‐2009 of which 4 joint publications Vaxinfectio‐CenStat in 2008 and 10 in 2009

Organisation of annual Methusalem Research Days Almost M€20 of external funding obtained in 2008

o Ranking third at UA o Ranking first compared to other medicine faculties in Flanders o Ranking first in terms of EU funding obtained o Vaxinfectio identified as company spearhead by the McKinsey Company

Large number of national and international collaborations (over 35 countries) Threats

Incompatibility of Methusalem Funding with BOF Funding Too few permanent staff employed jeopardizing future FP7, DG Sanco and other EU grant applications

Lack of mid‐level postdoctoral researchers leading to discontinuity of research Lack of (research) professorships at the Faculty of Medicine Lack of opportunity to be assigned as core facilities by the University of Antwerp Lack of space (labs/offices) Lack of support by central departments

- Methusalem Key Features -

6


1 Methusalem Consortium

1.1 Composition of the Methusalem Consortium The Methusalem Consortium is an interuniversity collaboration between:

• The Vaccine & Infectious Disease Institute ‐ Vaxinfectio, University of Antwerp • The Centre for Statistics ‐ CenStat, Hasselt University

- Methusalem Consortium -

8

UNIVERSITY of ANTWERP Methusalem Team leader: Prof. Dr. Herman Goossens Research Unit: University of Antwerp, Vaccine & Infectious Disease Institute: VAXINFECTIO Chair: Prof Dr. Pierre Van Damme Vice‐chairs: Prof. Dr. Herman Goossens & Prof. Dr. Zwi Berneman Research & Innovation Manager (IOF): Dr. Vanessa Vankerckhoven Administrative coordinator: Gino Verwimp Administrative staff: Emmy Engelen & Sophie Nys Participating Research Units in the Institute: 1) Centre for the Evaluation of Vaccination (CEV), Faculty of Medicine.

Head: Pierre Van Damme (100% ZAP) ‐ Koen Van Herck (10% ZAP)

Collaborating unit: Research Unit Health Economics and Mathematical Modelling of Infectious Diseases (CHERMID) Head: Philippe Beutels (100% ZAPBOF) ‐ Niel Hens (50% ZAP) ‐ Olivier Lejeune (100% postdoc BAP)

2) Laboratory of Medical Microbiology, Faculty of Medicine. Head: Herman Goossens (100% ZAP) ‐ Greet Ieven (10% ZAP) ‐ Katherine Loens (80% postdoc BAP) ‐ Surbhi Malhotra (100% postdoc BAP) ‐ Arno Muller (100% postdoc BAP)

Collaborating unit: Research Unit Infectious Diseases (RUID) Headed: Samuel Coenen (100% BAP Research Leader) ‐ Sibyl Anthierens (80% postdoc BAP)

3) Laboratory of Experimental Hematology (LEH), Faculty of Medicine.

Head: Zwi Berneman (100% ZAP) ‐ Peter Ponsaerts (100% postdoc BAP) ‐ Wilfried Schroyens (10% ZAP) ‐ Nathalie Cools (100% postdoc BAP) ‐ Katrien Vermeulen (100% postdoc BAP) ‐ Bart Tambuyzer (100% postdoc BAP)

Collaborating unit: Centre for Cell Therapy and Regenerative Medicine (CCRM), University Hospital Antwerp (UZA) Head: Viggo Van Tendeloo (100% ZAPBOF) ‐ Evelien Smits (100% postdoc BAP)


9

HASSELT UNIVERSITY Methusalem Team leader: Prof. Dr. Geert Molenberghs Research Unit: Center for Statistics (CenStat), Department of Mathematics, Physics and Computer Sciences. Head: Geert Molenberghs (100% ZAP) - Marc Aerts (100% ZAP) - José Cortiñas (100% postdoc BAP) - Christel Faes (100% ZAP) - Niel Hens (50% ZAP) - Ziv Shkedy (100% ZAP)

1.2 Management structure of the Methusalem Consortium Director: Prof. Dr. Herman Goossens Board of Directors: Chair: H. Goossens, Vice‐chair: G. Molenberghs Composed of the heads of the 4 participating core research groups, the (part‐time) ZAP members (8), all postdocs (12), Research & Innovation Manager, administrative coordinator, one administrative officer Department of Research (ADOC) and the chairman of the Research Council. Total: 28 members. Meeting frequency: at least once per year Board of Advisors: Chair: H. Goossens Composed of one administrative member ADOC and researchers with international recognition in the research field:

• Haruo Sugiyama, MD, PhD, Professor, Department of Functional Diagnostic Science Osaka University Graduate School of Medicine 1‐7, Yamada‐Oka, Suita City Osaka, Japan (confirmed);

• Ron Dagan, Professor of Pediatrics and Infectious Diseases, Ben Gurion University, and director of the pediatric infectious disease unit of Soroka University Medical Center and at Ben Gurion University, Beer‐Sheva, Israel (confirmed)

• Christopher C Butler, Professor and Head of Primary Care Medicine, Centre for Health Sciences Research, School of Medicine, Cardiff University (confirmed)

Meeting frequency: at least once per year

1.3 The Methusalem Consortium within the University of Antwerp & Hasselt University

Change in departmental structure of the Faculty of Medicine (UA) In 2007, the Vaccine and Infectious Disease Institute (Vaxinfectio), composed of three research units and three collaborating units (see 1.1), was founded within the University of Antwerp and more specifically within the Faculty of Medicine. At that time, the different research units were however not part of the same unit within the Faculty of Medicine:

• Laboratory of Medical Microbiology: part of Medical Genetics

- Methusalem Consortium -

10

• Laboratory of Experimental Hematology: part of Oncology • Center for Evaluation of Vaccination: part of Epidemiology and Social Medicine

In order to collaborate more closely and to enable submission of project proposals as one Institute (Vaxinfectio), a re‐assortment of the structure within the Faculty had to be implemented. After discussions with all spokesmen of the different existing departments within the Faculty Council, a consensus was reached on a new departmental structure and as of October 2009, all staff members of the Institute now belong to the same Department: Vaxinfectio. Within this unit, sub‐units have been formed, based on the specific research units composing the department and their leading researchers:

• Vaxinfectio‐Laboratory of Medical Microbiology (lead by Prof. Dr. Herman Goossens) • Vaxinfectio‐Center for Evaluation of Vaccination (lead by Prof. Dr. Pierre Van Damme) • Vaxinfectio‐Laboratory of Experimental Hematology (lead by Prof. Dr. Zwi Berneman)

Facilities (UA) Already at the start of the Methusalem funding in 2008, it became apparent that insufficient office and lab space was available to house all staff members that were part of the Consortium, in particular the staff of Vaxinfectio at the University of Antwerp. During the years 2008 and 2009, the number of staff even further increased within Vaxinfectio. Chapter IVbis of the Directive of the Flemish Government states the rules on Methusalem Funding. In this Chapter, Article 14decies §4 clearly states that ‘The University provides the necessary rooms and basic facilities to the ZAP member and his/her research group’. After numerous consultations and discussions with the UA rector, the UA general manager and his staff, a few possibilities were proposed to improve the lack of space. Currently, office and lab space is available for all staff members of the different research units, albeit with insufficient expansion opportunities for several of the research units and the staff scattered over the University Campus and the University Hospital. Moreover, the CHERMID and LMM staff is currently mainly located in former labs that were used by the Department of Pharmacy. Indeed, the staff is currently located on different floors of three buildings (R, S and T) at the UA Campus Drie Eiken, as well as at the site of the University Hospital (UZA). The CEV staff can be found on the second floor of Building R. The CHERMID staff is located on the 4th floor of Building S, together with part of the staff of LMM. The lab of LMM is situated on the 3th floor of Building S. The RUID staff is located in Building R on the 3th floor. LEH has a lab in Building T and the remainder of the staff as well as the CCRM staff is located at UZA. The plans to regroup the Institute in one location have been cancelled for the moment. Instead, in the coming years the staff of LMM will be joined on the 6th floor of Building S, together with the lab of LEH. The remainder of the LEH and CCRM staff will stay at UZA. The RUID staff will stay on the 3th floor of Building R. The CHERMID staff will be spread together with the CEV staff over the second floor of the R building and the 2nd floor of the S building.

Facilities (UHasselt) The Center for Statistics at Hasselt University (former Limburgs Universitair Centrum) was founded in May 1998 as a result of a growing applied statistics branch within the university. The scientific research conducted within the Center for Statistics (CenStat) is internationally renowned, both for its theoretical as well as for its applied component. Also the education and consultancy records are excellent. Over the years CenStat has collaborated with many (inter)national institutions within and outside UHasselt, of which a fruitful collaboration of more than a decade with CEV, UA and with the other Vaxinfectio institutes has led to its participation in the Methusalem Consortium. The Methusalem funding enables joining the expertise of Vaxinfectio and CenStat on a long term basis with shared appointments, enabling the consortium to play a pivotal role internationally. An ideal setting of what could become a more structural collaboration such as given by the unification of CenStat, UHasselt and the Biostatistical Centre at the Catholic University of Leuven in the Interuniversity Institute of Biostatistics and statistical Bioinformatics (I‐Biostat), anno 2008, strengthening both centres’ expertise in biostatistics, applied statistics and bioinformatics.


11

2 Objectives of the Methusalem Consortium The main basic research aim of the Consortium, is to study microbiological, immunological, mathematical‐biological, statistical, economical, societal and epidemiological aspects of infectious diseases and vaccines. The constituting research teams of the Consortium will use the Methusalem funding to create a science platform with an aim (1) to structure and consolidate the existing pool of knowledge and expertise in their respective

disciplines with targeted investments in qualified personnel, state‐of‐the‐art equipment and sufficient operational resources, and

(2) to advance knowledge and expertise in the listed scientific fields with focus on multidisciplinarity and based on the highest quality standards, with a view to attract additional resources and to increase its scientific output.

- Objectives of the Methusalem Consortium -

12


3 Research Activities 20082009

Figure 3.1: dynamics of the research within the Methusalem Consortium

Table 3.1 Overview of ongoing joint research activities

BASIC QUESTION CLINICAL RESEARCH BASIC RESEARCH PARTNERS

INVOLVED

A 1. Correlation of humoral

and cellular response in

vaccinees? Correlation with

protection?

2. Duration of cell‐

mediated immunological

(CMI) responses?

3.Immune tolerance

mechanisms in infectious

agents and tumours?

4. Mechanisms in non‐

response to vaccination

1. Vaccine studies CEV

2. Long‐term follow‐up

studies CEV

3. Phase I therapeutic DC

vaccines in tumour, HIV

and CMV patients

4. Vaccine trials CEV

(hepatitis B, influenza)

1. Analyzing vaccine‐induced

T cell responses by multi‐

parametric flow cytometry

and in vitro restimulation

cytokine assays

2. Modelling vaccine‐induced

cellular responses as a

function of time

3. in vitro studies of dendritic

cells and their interation on

suppressor T‐cells

4. Analyzing genetic factors

in non‐responders

CEV, LEH,

CenStat

- Research Activities 2008-2009 -

14

B 1. Role of TLR stimulation

in innate and adaptive

immunity to microbes and

tumours?

2. Role of TLR signalling and

the immune modulatory

effects of probiotic

lactobacilli

1. Therapeutic DC vaccine

trials

2. ‐

1. Effect of in vitro TLR3

signalling on the induction of

antiviral and anti‐tumoural T

cell responses.

2. Measuring TLR signalling

and effect of probiotics on

signalling, on transfected cell

lines and by ELISA.

LMM, LEH,

CenStat

C 1. impact of vaccination on

pneumococcal carriage?

2. impact of vaccination

programmes on

epidemiology of Hib,

rotavirus, pertussis and

meningococcus

1. oropharyngeal carriage

in (family contacts of)

infants during first year of

life

2. (molecular)

epidemiology in (family

contacts of) infants during

first year of life

1. & 2. Quantification of

penumococcal carriage,

serotyping by Quellung

reaction, strain typing by

multilocus sequence typing,

and antibiotic resistance

profiling by disk diffusion,

PCR and sequencing.

CEV, LMM,

CenStat

D Effect of using new

injection devices, adapted

administration route

and/or new adjuvant

formula on vaccine

efficacy?

Phase I trials using new

injection devices, new

administration routes or

new adjuvants with

existing vaccines

CMI analysis on vaccinees

Dendritic cells as nature’s

adjuvant

TLR ligands as adjuvants

LEH, CEV,

CenStat,

Artesis

E Local immune response in

vaccinees?

Phase I HPV trial Analyzing CMI responses in

cervical secretions

CEV, LEH

F 1. Neonatal/infant

immunity? Impact of

maternal antibodies?

2. Changes in the intestinal

microbiotome of infants

with asthma and effect of

prebiotics on the

development of asthma?

1. Longitudinal studies in

200 pregnant women and

their infants

2. Double blind placebo

controlled intervention

study on 200 neonates

1. Analysing humoral and

cellular immunity and

statistical modelling

2. Quantitative analysis of

faecal samples by phenotypic

methods and population

fingerprinting to

elucidate/type bacterial

species by denaturing

gradient gel electrophoresis.

CEV, LMM,

LEH, CenStat


15

G Kinetics of cellular‐

mediated immunity to

varicella zoster virus after

contact with a primary

case?

Longitudinal study in

contact persons of children

with primary varicella

infection

Analyzing vaccine‐induced T

cell responses by multi‐

parametric flow cytometry

and in vitro restimulation

cytokine assays

CEV, LEH,

CenStat

H Changes in the intestinal

microbiotome of patients

with irritable bowel

syndrome (IBS) and effect

of probiotics on IBS?

Clinical trial administering

probiotics to IBS patients

and healthy volunteers

Quantitative analysis of

faecal samples by phenotypic

methods and real‐time PCR

to detect differences in

bacterial genera and species.

LMM,

Censtat

I 1. Mechanisms of

resistance and phenotypic

tolerance selected by

amoxicillin therapy?

2. Mechanisms of

resistance and selection

dynamics of

fluoroquinolones (FQs),

ciprofloxacin and

levofloxacin exposure on

the human oropharyngeal

and gastrointestinal flora?

1. A randomized placebo‐

controlled prospective

study in patients with

community‐acquired lower

respiratory tract infections

conducted as part of the

ongoing FP6 project GRACE

and the ongoing FP7

project TheraEdge

2. A randomized placebo‐

controlled trial in healthy

volunteers

1. Quantitative analysis by

phenotypic methods of

changes in the oral

streptococcal flora and

genotypic methods to study

resistance mechanisms pre

and post‐amoxicillin therapy.

Analysing phenotypic

tolerance by spectrometric

quantification of elaborated

β‐lactamases and visualising

biofilm formation by FISH

analysis.

2. Quantitation of FQ‐

resistant Escherichia coli and

streptococci in faecal and

throat samples pre and post‐

therapy. Analysis of FQ‐

resistant mechanisms and

genetic relatedness of

isolates by PCR/sequencing,

SDS‐PAGE, growth inhibition

assays, and pulsed‐field gel

electrophoresis.

LMM, CEV,

CenStat

J Carriage and transmission

dynamics of (resistant)

bacteria?

Data from clinical trials in

section I

Deterministic dynamic

transmission models

CEV,

LMM,CenStat

- Research Activities 2008-2009 -

16

K Mechanism of innate

immunity in the central

nervous system?

‐ Development of multimodal

imaging strategies to

monitor inflammation and

cellular implants/vaccines in

the central nervous system.

LEH, CenStat

L Best strategy to diagnose

M. pneumoniae and C.

pneumoniae LRTIs?

A prospective study in

patients with community‐

acquired lower respiratory

tract infections

Evaluation of different tests

for the detection of

Mycoplasma pneumoniae

and C. pneumoniae in

patients with lower

respiratory tract infections

(LRTI)

LMM,

CenStat

M Antmicrobial consumption

and resistance patterns in

Europe

Assess the quality of

antimicrobial consumption

in ambulatory care,

hospital care and nursing

homes, explain variation,

and measure effect of

interventions

Time series and

compositional analysis of

longitudinal antimicrobial

consumption data, and

identification of appropriate

outcome measures

LMM,

CenStat

Please note that Table 3.1 gives an overview of the joint research activities, for a detailled overview of research projects; please consult Tables 7.1‐7.4.


4 Dissemination Activities

4.1 Scientific papers in peer reviewed journals Figure 3.1: Number of peer‐reviewed articles published in 2008 and 2009

Importantly, the Methusalem funding made an improved scientific collaboration with the University of Hasselt possible, which is clearly indicated by the increase in the number of joint publications, ie 4 in 2008 vs 10 in 2009. An overview of published papers and papers in press is given in Annex II, next to an overview of books and book chapters published by the Methusalem Consortium.

4.2 Yearbooks European Surveillance of Antimicrobial Consumption (ESAC) Yearbooks ESAC Yearbook 2006 (ISBN 978‐90‐5728‐094‐8) ESAC (European Surveillance of Antimicrobial Consumption) is an international network of national surveillance systems, collecting comparable and reliable antibiotic use data granted by ECDC (European Centre for Disease Prevention and Control; Grant Agreement GRANT/2007/001). The ESAC yearbook 2006 covers the 1999‐2006 consumption data for antimicrobials for systemic use (Anatomical Therapeutic Chemical (ATC) group J01), antimycotics for systemic use (ATC group J02) and additional specific substances i.e. the data available in the ESAC database which were collected by the ESAC Management Team in 2007. Of the 35 participating countries, 21 were able to deliver outpatient data, 14 hospital data and 4 total data including both sectors together for 2006. Additionally, for each of the countries that provided data a country sheet summarizing their data is available in the yearbook. A PDF version of the ESAC yearbook 2006 can be consulted on the ESAC website: www.esac.ua.ac.be ESAC Yearbook 2007 (ISBN 978‐90‐5728‐124‐2) The ESAC yearbook 2007 covers the 1999‐2007 consumption data for antimicrobials for systemic use

- Dissemination Activities -

18

(ATC group J01), antimycotics for systemic use (ATC group J02) and additional specific substances i.e. the data available in the ESAC database which were collected by the ESAC Management Team in 2008. Of the 35 participating countries, 22 were able to deliver outpatient data, 15 hospital data and 3 total data including both sectors together for 2007. Also, an overview is given of the in‐depth analyses on ambulatory care, hospital care, nursing homes, and socio‐economics. Additionally, for each of the countries that provided data a country sheet summarizing their data is available in the yearbook. A PDF version of the ESAC yearbook 2007 can be consulted on the ESAC website: www.esac.ua.ac.be

4.3 Workshops/Conferences/summer course

Methusalem Research Days On September 4, 2008, the first joint scientific meeting of the Methusalem Consortium was held. The purpose of this meeting was twofold: to present the consortium and its research programmes and to highlight ongoing and planned collaborations between UA and UH. These meetings will be held on an annual basis. The first Research Day attracted a total of 65 participants, including the UA rector (at that time: F. Van Loon), the chairman elect of the Research Council and the dean of the Faculty of Pharmeutical, Biomedical, and Veterinary Sciences. On October 22, 2009, the second joint scientific meeting of the Methusalem Consortium was held. The purpose of this meeting was to present ongoing collaborative research between UA and UH was has significantly grown since the start of Methusalem in 2008. This second Research Day attracted a total 58 participants, which was slightly lower than the first edition, but this might be due to the late annoucement of the event. Interestingly, the Research Day did attract researchers outside the Methusalem Consortium, including LMPH (Laboratory of Microbiology, Parasitology, and Hygiene), ITG (Institute of Tropical Medicine), and AMBIOR (Applied Molecular Biology Research group). Next to a scientific meeting, both Methusalem Research Days also provided the ideal opportunity to bring together the different members of the Board of Directors. For programmes of the Methusalem Research Days see Annex III.

Valentijn Vaccinatiesymposium In 2008 and 2009, the 6th and 7th edition of the Valentijn Vaccinatiesymposium, organised by CEV, were held. The purpose of these conferences is not as much to transfer scientific knowledge, but rather to offer high quality presentations on applied live topics. The programme for 2010 will for instance cover H1N1 influenza (epidemiology and vaccines) as well as longterm vaccine‐induced protection. Information on these conferences can be found on: www.ua.ac.be/valentijn. Since its start, the Valentijn Vaccinatiesymposium attracted more than 250 participants each year. In 2009 we welcomed the participation of the Minister of Health of the Flemish Community, who presented his point of view on the vaccination policy in Flanders.

Scientific Chair in Evidence Based Vaccinology Background: The need was felt among the researchers of both Vaxinfectio and CenStat to set up a more comprehensive research and education plan of action in the field of evidence based vaccinology, as part of the overall research plan of the Methusalem consortium. It was opted to establish a scientific chair, in order to make it possible to attract funding from various sources, including from private sector. The promotor of the Chair is Prof. Dr. Philippe Beutels, head of the Centre for Health


19

Economics Research and Modelling Infectious Diseases (CHERMID); Prof. Dr. Pierre Van Damme, head of the Centre for the Evaluation of Vaccination (CEV) and President of Vaxinfectio, acts as co‐promotor of the Chair. The Scientific Chair in Evidence Based Vaccinology (EBV) was officially established by decision of the UA Board of Directors (Bestuurscollege) on December 9, 2008. Funding for the EBV Chair has meanwhile been secured from Wyeth for three years (60.000 EUR annually). Holder of the EBV Chair: As of 1st February 2009, Dr. Niel Hens has been selected as holder of the Chair. He has been appointed as 50% Guest Professor, and combines this assignment with a position as doctoral researcher at the University of Hasselt. He holds a PhD in science (mathematics) and he has an excellent track record in terms of research and education. His doctoral research has been on the crossroads between the disciplines of medicine, mathematics and statistics. His curriculum lists several international awards, refereeing for international peer reviewed scientific journals, supervising PhD students, publications as first author, presentations at international conferences, workshops and symposia, as well as involvement in large research projects. His appointment serves as a continuation of the intensive relationship between UH and UA. Scientific objectives of the EBV Chair: The EBV Chair will support research into improved estimation methods to establish the effectiveness and cost‐effectiveness of vaccination programmes, including pneumococcal conjugate vaccine programmes, as well as medical education in evidence based vaccinology. The scientific aim of this Chair is to raise the level of scientific research in the area of evidence based vaccinology, in order to match the growing scientific interests from academics and industry, and in order to achieve a high level of independent research in this area. Activities to be developed by the EBV Chair:

• The further development and refinement of scientific research in evidence based vaccinology, comprising estimating the efficacy, effectiveness and cost‐effectiveness of vaccination programmes by infectious disease modelling.

• The establishment of various external scientific activities in the area of evidence based vaccinology (symposia, workshops, and conferences), in order to translate the results to the national and international public health community.

• The improvement of course modules on the subject area used in tertiary education. • Supervision of MSc and PhD dissertations in the field of evidence based vaccinology.

The inaugural lecture ‘Current Topics in Vaccinology: from Basic ``Who Infects Whom'' Research to Modelling H1N1 Flu’ was organised on September 23, 2009.

ESAC Meetings ESAC (European Surveillance of Antimicrobial Consumption; www.esac.ua.ac.be) is an international network of national surveillance systems, collecting comparable and reliable antibiotic use data granted by ECDC (European Centre for Disease Prevention and Control; Grant Agreement GRANT/2007/001). Structure and modus operandi: The structure of ESAC includes the ESAC Management Team (MT), ESAC Scientific Advisory Board (SAB), ESAC Audit Committee (AC), and ESAC National Networks (NN). A multi‐disciplinary MT (with expertise in information technology, data management, microbiology, infectious diseases, epidemiology, ambulatory care medicine, hospital care medicine, pharmacology, and health economics) was installed at the Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp but also has members in Brussels, Dundee (UK) and Ljubljana


20

(Slovenia). This MT ensures day‐to‐day management and monitoring of the network activities. Participating countries have established NN consisting of relevant experts in the field of antimicrobial consumption. These networks are coordinated by Lead National Representatives (LNR). The SAB provides scientific support to the MT and liaises with ECDC as well as EU funded projects on antimicrobial use and resistance, whereas the AC monitors the progress of the project and helps resolve problems. ESAC Meetings: ESAC organizes subprojects meetings, at least one SAB meeting per year where the strategy is discussed and approved, at least one AC meeting during which output is evaluated and one annual meeting during which the LNRs from the 35 participating countries (27 member states, 3 applicant countries and 5 others) gather and discuss the ESAC results on antimicrobial consumption as well as the results obtained from the subprojects on ambulatory care (AC), hospital care (HC), nursing homes (NH), and socio‐economics (EC).

• NH/HC Subproject meeting (Aug 31‐ Sept 1, 2009, Lisbon, Portugal) • AC/EC Subproject meeting (Jun 23, 2009, Antwerp, Belgium) • Second ESAC annual meeting (Nov 13‐14, 2008, Athens, Greece) • AC/EC Subproject meeting (Jun 24, 2008, Antwerp, Belgium) • NH/HC Subproject meeting (Feb 12‐13, 2008, Brussels, Belgium) • First ESAC annual meeting (Nov 15‐16, 2007, Antwerp, Belgium)

GRACE Meetings/workshops GRACE (Genomics to combat Resistance against Antibiotics in Community‐acquired LRTI in Europe; www.grace‐lrti.org) is a Network of Excellence focusing on the complex and controversial field of community‐acquired lower respiratory tract infections (CA‐LRTI), which is one of the leading reasons for seeking medical care. The promiscuous use of antibiotics to treatment of CA‐LRTI accounts for a major part of the community burden of antibiotic use and contributes dramatically to the rising prevalence of resistance among major human pathogens. The overall objective of GRACE is to combat antimicrobial resistance through integrating centres of research excellence and exploiting genomics in the investigation of CA‐LRTI. Microbial and human genomics are integrated with health sciences research consisting of clinical observational and intervention studies, health economics and health education to specifically change practice in managing CA‐LRTI. GRACE is exceptional as it brings together 28 academic groups with a wide spectrum of expertise, spread widely across 13 EU Member States, and 4 SMEs. GRACE organises professional education, through two leading European scientific societies (European Society of Clinical Microbiology and Infectious Diseases and European Respiratory Society). Structure and modus operanding: The structure of GRACE includes the GRACE management team, the Governing Council (GC), Executive Council (EC), the Scientific Advisory Board (SAB), the Patient Advisory Board (PAB), and the Ethics Management Unit (EMU). A multi‐disciplinary management team was installed at the Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp. This management team ensures day‐to‐day management and monitoring of the project activities. The GC consists of all partners and the project‐manager. The partners have responsibilities for the objectives set up for the workpackages to which they contribute. The EC consists of the GRACE Network co‐ordinator, the WP leaders, and the project manager. The WP leaders have management responsibilities for their contribution to the project, are responsible for the content of their WP and the partners involved as described in the proposal. The EMU will take into account the multidisciplinary nature of ethical issues (e.g. data protection, animal testing, placebo in clinical trials) arising in the conduct of the project. The SAB and PAB provide scientific input on the progress of the project.


21

GRACE meetings, workshops and postgraduate courses: Both the European Respiratory Society and the European Society of Clinical Microbiology and Infectious Diseases are providing an educational programme to spread knowledge to those working in this field and to the wider public in Europe. Content from previous courses and educational documents can be found through an open access portal: http://www.grace‐edut.org/pages.

• 4th GRACE Postgraduate Course ‐ ECCMID, Barcelona 2008: Defining the burden of antibiotic resistance and LRTI

• 5th GRACE Postgraduate Course ‐ ERS, Berlin 2008: Antibiotics or not: from acute bronchitis to acute exacerbation of chronic bronchitis

• 6th GRACE Postgraduate Course, ECCMID Educational Workshop, Helsinki, Finland, 16 May 2009: Challenges and Change in Pneumonia – Focus on Streptococcus pneumoniae and Community‐acquired MRSA

• 7th GRACE Postgraduate Course, ERS Educational Workshop, Vienna, Austria, 12 September 2009: Vaccination and Preventive Measures for LRTI in the Community

• 3rd GRACE Workshop, Cambridge 2008, ECCMID Educational workshop: The science, practice and challenges of LRTI in primary care

• 4th GRACE Workshop, in collaboration with ESCMID, Rome, Italy, 23 – 24 October 2009: New Challenges in Primary Care: Back to the Future

• 5th GRACE Workshop, ECCMID Educational Workshop, Vienna, Austria, 10‐13 April 2010: Viruses and the respiratory tract – current and future issues

Meetings • GRACE 3rd annual meeting (Milan, March 19‐20, 2009) • GRACE meeting Cambridge (Cambridge, September 18, 2008) • GRACE 2nd annual meeting (Budapest, March 6‐7, 2008)

VHPB Meetings The objective of VHPB (Viral Hepatitis Prevention Board; www.vhpb.org) is to contribute to the control and prevention of viral hepatitis, by drawing the attention to this important public health problem, by issuing prevention guidelines, and by encouraging actions to improve control and prevention. VHPB focus audiences are, in the first instance, health care professionals, policymakers, and opinion leaders in Europe. VHPB has, in support of its main objective, a wide range of functions, including the following:

• To monitor and evaluate the currently implemented immunisation programmes. • To bring together, during VHPB meetings, an international forum of specialists to examine,

discuss, and judge on specific topics, closely related with the control and prevention of viral hepatitis.

• To produce and distribute a number of publications, including Viral Hepatitis, a newsletter on viral hepatitis and reports of VHPB meetings.

• To disseminate viral hepatitis control and prevention guidelines for the health care workers and policymakers.

• To closely collaborate with international agencies dealing with control and prevention of viral hepatitis (World Health Organization, Centres of Disease Control and Prevention, European Centre of Disease Prevention and Control, Bill and Melinda Gates Children's Vaccine Program, European Commission, and Non Governmental Organisations) in order to maximise the impact of the efforts.

• To organise international meetings to facilitate the introduction of immunisation programmes.

• To promote the implementation of WHO recommendations on viral hepatitis control and prevention.

• To assist implementation of national plans of action for the introduction of vaccines


22

Structure and modus operandi: The structure of the VHPB includes an executive secretariat, advisory members, and honorary members. The executive secretariat is located at the Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp. The advisory members, internationally recognised experts in the field of viral hepatitis, come from international organisations, academia, and/or national health authorities. The VHPB executive secretariat sets the strategy, defines the actions, and prepares the meetings of the VHPB, all of this in consultation with the VHPB advisory members. Advisory members are appointed for a period of three years, on a renewable basis. VHPB Meetings: The VHPB has at least two adviser meetings per year where the strategy is discussed and approved, meetings prepared and output evaluated:

• Prevention and control of viral hepatitis: The role of patient and advocacy groups in and outside Europe, 13‐14 March 2008, Lucca, Italy. This special VHPB meeting provided an overview of the activities, role, rationale and impact of several liver patient and advocacy groups in Europe and the US. Examples of experiences of international and national liver patient and advocacy groups were presented and challenges and thresholds experienced by liver patient and advocacy groups regarding their role and impact on prevention and control of viral hepatitis were identified during the meeting.

• Prevention and control of viral hepatitis in the Netherlands: lessons learnt and the way forward, 13‐14 November 2008, Rotterdam, the Netherlands. This meeting fully focused on the Netherlands and reviewed the organization of the healthcare system, the epidemiological situation, surveillance system, research activities, and current prevention and control measures of viral hepatitis. The timing of this VHPB meeting was particularly interesting as the Dutch Ministry of Health was re‐evaluating the possible introduction of universal hepatitis B vaccination into the National Immunization programme.

• Hepatitis A and E: Update on Prevention and epidemiology, 12‐13 March 2009, Antwerp, Belgium. In March 2009 the Viral Hepatitis Prevention Board (VHPB) organized a meeting in Antwerp, in order to review the status of epidemiology and prevention of both hepatitis A and E. Main topics related to Hepatitis A (HAV) included feedback of the Global HAV meeting held in December 2007 in Miami, and related lessons learned for the WHO European region. Recent information on HAV epidemiology, outbreaks and prevention was also provided and future initiatives were discussed among participants. With regards to Hepatitis E (HEV), an overview of HEV virology and the disease was given together with its worldwide epidemiology, including data suggesting zoonotic transmission. The emergence of HEV in non‐endemic/endemic countries was assessed and future opportunities of an HEV vaccine were discussed.

• Burden and prevention of viral hepatitis in Turkey, 12‐13 November 2009, Istanbul, Turkey. Ten years after the introduction of universal Hepatitis B vaccination in Turkey a meeting was organized to review the organization of the health care system, the current surveillance systems and the epidemiological situation. Successes, problems and barriers to overcome and the possible implementation of new prevention and control measures and improvements on the monitoring systems were also discussed.

Summer Course in Vaccinology Within the framework of the EU‐VACSATC, a European collaboration project with 14 countries, a clear need to improve training of healthcare workers on aspects of vaccines and vaccinations, including vaccine safety and communication with health consumers was identified. The organization of both the vaccination services and the education system are far from uniform in the different


23

European Countries. Research showed that healthcare workers, regardless of their professional involvement in immunization, are the major source for information on immunization and vaccine safety. However in pre‐service training the topic is usually spread over several courses leaving most doctors and nurses, with too little training to communicate with healthcare consumers regarding the benefits and safety of vaccines. With an exception of healthcare workers who receive post‐graduate or in‐service training on vaccination there is insufficient objective knowledge on immunization and vaccine safety to achieve and maintain high vaccine uptake. The Vaccine & Infectious Disease Institute (VAXINFECTIO) of the University of Antwerp, as chair of the work package responsible for the improvement of pre‐service immunization training of health professionals, developed a set of criteria for good pre‐service training in immunization and vaccine safety based on the national minimum standards for (in‐service) immunization training developed by the Health Protection Agency in the UK. Building upon these documents and as an answer to a clearly identified gap in the pre‐service training of medics and paramedics in Europe, the University of Antwerp organized in July 2009 a 5 day summer school as a pilot training program, “the summer school on Vaccinology”. In addition the summer school will contribute to the development and evaluation of generic education packages in accordance with the set of minimum criteria for good immunization and vaccine training. Ideally universities and other higher education institutes across Europe will incorporate them in their curricula which however will be a long and slow process. Therefore we feel the need to offer this subject in an international summer school with a panel of high level experts and practical training. An initiative we plan to continue and develop further in the future. The summer school on Vaccinology 2010 is being prepared now, based on the lessons learned from the first edition. The proposed training focuses on the aspect of immunization and vaccine safety. It is a basic course mainly targeted to students but applications of in‐service healthcare workers will be considered. Basic knowledge of immunology will be required to enroll. The content as well as the practical organization are discussed and validated by students through close cooperation with EMSA‐Antwerp vzw, the local branch of the European Medical Students Association. Training objectives:

- To be able to describe the history of vaccination in the world and in Europe. - To know the basic concepts of immunology and vaccine immunology and epidemiological

and ecologic principles underlying infection spread. - To know and understand the types, composition and development of vaccines. - To be able to describe and recognize the main features of vaccine preventable diseases and

the nature and frequency of their acute and long term complications. - To be able to use immunization techniques, to follow correct procedures for storage and

handling of vaccines, to reconstitute and administer vaccines correctly and to manage anaphylaxis and other adverse events correctly.

- To be able to explain the aims of immunization, describe national policy and schedules and to deal with variations to the schedule.

- To understand the health economic basis of an evaluation of a vaccination program. - Increased awareness and capacity to respond to current issues and controversies regarding

immunization. - To be able to find and assess the reliability of information sources. - To be able to communicate effectively with patients and parents about vaccination. - To have knowledge of the future perspectives on vaccine development.

Training methodology: During the training a mix of teaching methods are used used including different interactive teaching


24

methods, lectures of experts, individual ‐ and group works as well as practical training. Next to a baseline knowledge and skills test, the students are evaluated on an ongoing basis as well as in the end. Also the set‐up and the effectiveness of the course program and used methodology are evaluated. ECTS accreditation for the course has been obtained (3 ECTS credits).

AUHA Research Days The second Research Day entitled ‘Research & Industry – Partners with a future perspective’ was organised by AUHA (Associatie Universiteit & Hogescholen Antwerpen) and held on February 27, 2008. During this research day examples of solid collaboration within AUHA and companies were presented. The specific themes were chosen based on the strategic (innovation)clusters laid down by the Flemish Board for Science (VRWB). The main focus groups are all involved or interested in education within AUHA, but also outside of AUHA. The research days aim to attract companies in particular. Vaxinfectio presented their fields of research of interest to companies and members of AUHA in order to seek opportunities for future collaborations; more specifically the Nanovax study (Development of a new device for intradermal delivery of vaccines) was presented.

4.4 Intellectual property rights Already within Vaxinfectio and later within the Methusalem Consortium, the need for a manager became apparent. Vaxinfectio applied for a managerial position in 2008 and in 2009, such a position was offered at the University of Antwerp to recruit a research and innovation manager (funded by the Industrial Research Fund) for Vaxinfectio. The recruitment was only recently finished and the newly appointed research and innovation manager (Dr. Vanessa Vankerckhoven) has started as of Nov 1, 2009. With regard to technology transfer and intellectual property rights (IPR) efforts will be made by the research and innovation manager to raise awareness among the researchers of the Consortium concerning the valorisation of research results and the possibilities concerning commercial exploitation thereof. Also, she will participate in the information sessions that are organised by the interface services of the Universities of Antwerp and Hasselt and will closely collaborate with their staff on valorisation of results, licensing deals, spin‐offs possibilities and other technology transfer opportunities. The research and innovation manager will, in line with the UA and the UH rules and regulations, give special attention to a policy of technology transfer. All inventions or research results with commercial potential will be discussed with the research and innovation manager who will report to the interface services of UA and UH. The Board of Advisors of the Consortium will advise on the names of the inventors. The research and innovation manager will work closely with the interface services to determine the best strategy to market any invention (patenting, licencing, spin‐off,...). Eventual profits (1/3 that goes to the Consortium according to University regulations) will be reinvested in the research capacity of the Consortium to further support the planned research. In addition to the recent appointment of a research and innovation manager, an IOF project entitled ‘Creation of a translational platform for integrated vaccine research’ was approved by RIOFI (Board for Industrial Research Funding) at UA and will be funded for a period of 4 years. The project entails a close collaboration with GlaxoSmithKline Biologicals (Rixensart, Belgium) as industrial partner. Next to several scientific outcomes, the project also offers a large technology transfer potential, e.g. patents and spin‐offs. The research and innovation manager will closely monitor the project in terms of technology transfer opportunities in collaboration with the interface service at UA.


25

5 Communication

5.1 Press releases The leading researchers already had a proven track record in terms of communication with the press and the wider general public. This track record was further substantiated in 2008 and 2009. An overview is given below.

International press releases Major new study holds the key to antibiotic over‐prescribing for lower respiratory tract infections across Europe, BMJ Media Release, embargo: 00:01 hrs (UK time) on Wednesday 24th June 2009.

National press releases on the website of University of Antwerp

2009

Moeten we vaccineren tegen Hepatitis A? Philippe Beutels

Twee primeurs op het 7de Valentijn Vaccinatiesymposium op 13‐2‐09 Pierre Van Damme

Betere wetgeving voor veiligheid probiotica nodig Vanessa Vankerckhoven

Universiteit Antwerpen test vaccin tegen Mexicaanse griep Pierre Van Damme

Article Prof.H.Goossens in Maguza (21 Jan. 2009) Herman Goossens

Nieuw onderzoek sleutel tot aanpak overgebruik antibiotica bij lageluchtwegeninfecties Herman Goossens

Major new study holds the key to antibiotic over‐prescribing for lower respiratory tract

infections across Europe

Herman Goossens

EUROPEAN ANTIBIOTIC AWARENESS DAY Herman Goossens

2008

6e Valentijn Vaccinatiesymposium op 15 februari 2008 Pierre Van Damme

Prinses Mathilde bezoekt het Centrum voor de Evaluatie van Vaccinaties van de UA Pierre Van Damme

Een Belg praat met gemiddeld 12 personen per dag Philippe Beutels

Leeftijdsgrens stamceltransplantatie schuift op Zwi Berneman

Universiteit Antwerpen leidende rol in organisatie Geneeskundige Dagen Antwerpen Pierre Van Damme

Universiteiten van Antwerpen en Hasselt starten een intensieve samenwerking rond

infectieziekten en vaccins

Herman Goossens

Videotape: Belgen slikken een derde minder antibiotica Herman Goossens

5.2 Website To enhance the visibility and to improve dissemination activities within the Consortium, a website was created. The website can be accessed through: www.vaxinfectio.be, www.vaxinfectio.org, www.vaxinfectio.eu and www.vaxinfectio.com. Next to information on the Centre of Excellence, Vaxinfectio, also information on Methusalem is available (see parts below). The website is hosted by the University of Antwerp. It is available in English and contains the following parts:

• Structure

- Communication -

o The composition of the Vaxinfectio governing council • Research

o Methusalem o Major projects o EU‐funded projects o Chair in Vaccinology

• Dissemination o Papers o Abstracts o Press releases o Newsletters

• Events o Announcement of workshop/conferences

• News o Recent press releases and important information related to activities within the

consortium • Staff • Useful links • Job vacancies • Contact

The website will be revised shortly to create a higher visibility of the Methusalem Consortium, including management structure, staff and dissemination. Also, an electronic library will be added to the dissemination part of the website. This library will contain all publications of the consortium. The e‐library will have an easy‐to‐use search engine, enabling searches by author, publication date, keywords and/or journal. Figure 5.1: Screenshot homepage Vaxinfectio website

5.3 Newsletters GRACE News GRACE issues a 3‐monthly newsletter which reports on the progress of GRACE activities since the


27

official launch March 17, 2006 in Brussels. More information and issues of the newsletter are available at: https://www.grace‐lrti.org/portal/en‐GB ESAC Newsletter The ESAC newsletter is made available 3 times per year. In each of the newsletters 4 of the National Networks present themselves and news on the core data and/or the subprojects is presented. Upcoming events are announced and previous events such as congresses are discussed. A PDF version of the ESAC Newsletters can be downloaded from the ESAC website: http://www.esac.ua.ac.be. The Viral Hepatitis Newsletter VHPB provides a forum for experts to exchange ideas and to develop consensus guidelines and recommendations on issues related to viral hepatitis prevention and control. Most of its findings, actions and meeting reports are published in the VHPB newsletter 'Viral Hepatitis', which is distributed to a list of more than 4000 members. The VHPB newsletters can be found on the website: www.vhpb.org.

- Communication -

28


29

6 International and National Collaborations

6.1 Strategic collaborations with other research groups & industry

National Collaborations At the start of the Methusalem funding relationships with a number of other research groups in and outside the University had already been established.

• Joint projects with other Universities funded by FWO, IUAP, IWT, and EU o IUAP project entitled "Inhibition of HIV replication" HIV‐STOP (# P6/41); Promotor:

UA (Berneman/Van Tendeloo), co‐promotors: Institute of Tropical Medicine (ITG; G. Vanham), UGent (B. Verhasselt), KUL (A. Van Damme), ULg (M. Moutschen) and VU Amsterdam (B. Berkhout)

o IWT‐TBM project entitled ‘A phase I/II study of therapeutic vaccination with autologous dendritic cells of HIV infected individuals under stable HAART’; Promotor VUB (K. Tielemans); co‐promotor: UA (Z. Berneman)

o Foundation against cancer project entitled ‘Dendritic cell vaccination against human cytomegalovirus in leukemia patients following allogeneic hematopoietic stem cell transplantation: A phase I/II study’, collaboration with University of Liège (Y. Beguin)

o FWO project with VUB/VIB ‘Identification of novel surface‐expressed factors mediating virulence and biofilm formation in methicillin‐resistant Staphylococcus aureus’ Promoter: UA (Herman Goossens); copromoters UA (Surbhi Malhotra), VUB/VIB (Henri De Greve), VUB (Jean‐Pierre Hernalsteens)

• The University Hospital (UZA) o Use of the Clinical Research Unit o Collaboration with several units (gynecology, paediatrics, …)

• The Institute of Tropical Medicine (ITG) o GOA project entitled ‘Induction of immunity and tolerance by dendritic cells in

cancer and AIDS’ in collaboration with Guido Vanham o IUAP project entitled "Inhibition of HIV replication" HIV‐STOP (# P6/41); in

collaboration with Guido Vanham o IWT‐TBM project entitled ‘A phase I/II study of therapeutic vaccination with

autologous dendritic cells of HIV infected individuals under stable HAART’ in collaboration with Guido Vanham

o FWO project entitled ‘Mechanisms of secondary control of HIV infection after an episode of anti‐retroviral treatment’ in collaboration with Guido Vanham

• Institute of Public Health o Collaboration within the framework of the European Surveillance of Antimicrobial

Consumption (ESAC) project (Funded by DG Sanco) • Industry

o Coris BioConcept within the framework of the EU‐FP6 project Grace During 2008‐2009, the Consortium has fostered these existing relationships, but has also developed new relationships with new groups.

• University of Antwerp

- International and National Collaborations -

30

o Collaboration with LMPH (Prof. Dr. L. Maes and Prof. Dr. P. Cos) o Collaboration with AMBIOR (Prof. Dr. JP Bogers) o GOA project entitled ‘Infectious disease models: wildlife ecology, ecological

disturbance and transmission to humans’ (Prof. Dr. Herwig Leirs) • AHUA

o IOF project ‘Creation of a translational platform for integrated vaccine research’ with the department of Product Development at Artesis (Dr. Stijn Verwulgen)

• Joint projects with other Universities funded by FWO, IUAP, IWT, and EU o Ghent University (P. Bienstman) within the framework of the EU‐FP7 project

Intopsens o IWT‐SBO project entitled ‘Simulation models of infectious disease transmission and

control processes – SIMID’; promotor: Prof. Dr. Philippe Beutels (UA), co‐promotors Marc Van Ranst (KuLeuven), Marc Aerts (UHasselt), Herman Van Oyen (IPH)

o IWT‐SBO project entitled ‘Non‐invasive imaging of migration and survival of stem cells in the brain – BRAINSTIM’; promotor: Prof. Catherine Verfaillie (KuLeuven – SCIL); co‐promotors: Prof. Zwi Berneman & Prof. Annemie Van der Linden (UA); Prof. Veerle Baekelandt & Prof. Koen van Laere (KuLeuven), Prof. Stefaan De Smedt (Ghent University).

o FWO project entitled ‘Clinical and preclinical research of the effect of cellular mediators on the modulation of pathogenic responses in multiple sclerosis’ in collaboration with UHasselt (P. Stinissen)

o Université Libre de Bruxelles (M. Struelens) within the framework of the EU project ESAC

o Ghent University (T. Decorte) within the framework of DRUSEB (Drug use among female sex workers in Belgium; funded by BELSPO)

• Industry o Wyeth: Scientific chair on Evidence Based Vaccinology (Prof. Dr. Niel Hens) o GSK: IOF project ‘Creation of a translational platform for integrated vaccine research’ o Algonomics within the framework of technology exchange

• Institute of Public Health o IWT‐SBO project entitled ‘Simulation models of infectious disease transmission and

control processes – SIMID’ (Prof. Dr. Philippe Beutels) o EU‐ESAC project (entitled ESAC‐3, funded by ECDC)


International Collaborations The Methusalem Consortium has built‐up an international network and currently collaborates with 153 scientific and industrial partners worldwide (37 countries). Country Name Institute / Organisation Contact Person Type of Institute /

Organisation Type of project involved

Austria Elisabethinen Hospital Linz Helmut Mittermayer academic EU Other

Bulgaria National Center of Infectious and Parasitic diseases Mira Kojouharova public organisation EU Other

Bulgaria Transport Medical Institute Miteva Boyka industrial partner EU Other

Bulgaria University Multipurpose Hospital for Active Treatment "Aleksandrovska" Boyka Markova academic EU Other

Croatia University Hospital for Infectious Diseases Croatia Arjana Tambic Andrasevic academic EU Other

Cyprus Ministry of Health of Cyprus Antonis Kontemeniotis public organisation EU Other

Czech Republic Univerzita Karlova Vlcek Jiri academic EU Other

Denmark Aarhus Universitet Martin Kristensen academic EU FP 7

Denmark Righospitalet Peter Garred public organisation EU FP 6

Denmark Statens Serum Institut Niels Frimodt‐Møller academic EU Other

Denmark WHO Regional Office Europe Nedret Emiroglu public organisation Research collaboration

Estonia State Agency of Medecines Ly Rootslane public organisation EU Other

Estonia University of Tartu Irja Lutsar academic EU Other

Finland Mobidiag Ltd Jaakko Pellosniemi SME EU FP 7

Finland National Institute of Health and Welfare Jaana Vuopio academic EU Other

France AbAg Camille Cyncynatus industrial EU FP 6

France Agence Française de sécurité sanitaire des produits de santé Philippe Cavalié public organisation EU Other

France ARTTIC Andrea Kuperberg SME EU FP 7

France Centre Hospitalier Universitaire de Nice Pia Touboul academic EU Other

France Commissariat à l’ Energie Atomique (CEA), Paris Roger Legrand research institute Agence National de Recherche sur le SIDA

France Fondation Hôpital Saint Joseph Laurent Gutman academic EU FP 7


Country Name Institute / Organisation Contact Person Type of Institute / Organisation

Type of project involved

France French National Institute for Research in Computer Science and Control Eric Fleury research Institute EU FP 6

France INSERM (French National Institute of Health and Medical Research) Christian Brun‐Buisson research Institute EU FP 6

France Institut Cochin Paris Anne Hosmalin research institute Agence National de Recherche sur le SIDA

France Pasteur Institute Didier Guillemot academic EU Other & EU FP 6

France Université Paris 5 Françoise Roudot‐Thoraval academic Research collaboration

France Université Paris‐Val de Marne Isabelle Durand‐Zaleski academic EU FP 6

Germany AmpTec GmbH, Hamburg Guido Krupp industrial EU FP 6

Germany Array‐On Gmbh, Gatersleben Dirk Fischer industrial EU FP 6

Germany BAG Health Care GmbH, Lich Nicolas Sachsenberg industrial EU FP 6

Germany Diakoniekrankenhaus Rotenberg Gmbh, Rotenburg Tom Schaberg industrial EU FP 6

Germany Institut fur Mikrotechnik Mainz Gmbh Klaus Stefan Drese SME EU FP 7

Germany The European Society for Paediatric Infectious Diseases, Muenchen Maria Tsolia European organisation EU Other

Germany Universität Kaiserlautern, Kaiserlautern Regine Hakenbeck academic EU FP 6

Germany Universitât Würzburg Ulrich Dobrindt academic EU FP 7

Germany University Bielefeld Markus Sauer academic EU FP 7

Germany University Dresden Petra Schwille academic EU FP 7

Germany University Hospital Center for Infectious Diseases and Travel Medecine Freiburg Winfred V.Kern academic EU Other

Germany University Medical Center Freiburg Philipp Henneke academic EU Other

Germany University of Rostock Michael Schmitt academic EU FP7‐SCALA (pending)

Germany Universitätsklinikum Charité Johannes Hallauer academic Research collaboration

Germany University of Regensburg Wolfgang Jilg academic Research collaboration

Greece National and Kapodistrian University of Athens Maria Tsolia academic EU Other

Greece National School of Public Health J.Kourea‐Kremastinou academic EU Other

Greece University General Hospital ATTIKON Helen Giamarellou academic EU Other

Greece National School of Public Health Georges Papaevangelou academic Research collaboration




Hungary University of Pecs Gabor Ternak academic EU Other

Iceland Landspitali University Hospital Karl G.Kristinsson academic EU Other

Ireland Sta National Disease Surveillance Centre Robert Cunney academic EU Other

Israel Infectious Diseases Unit Raul Raz academic EU Other

Israel Tel‐Aviv Sourasky Medical Centre (Fund‐Tasmc) Yehuda Carmeli academic EU FP 6 & EU FP7

Israel Ben‐Gurion University of the Negev Dagan Ron academic Research collaboration

Israel Nanopass Yotam Almagor industrial Clinical trials

Italy Agenzia Italiana del Farmaco Pietro Folino Gallo public organisation EU 90 ‐ 10

Italy Consorzio per Valutazioni Biologiche e Farmacologiche Adriana Ceci public organisation EU Other

Italy Fondazione Penta Carlo Giaquinto public organisation EU Other

Italy INSERM‐Transfert Jerome Weinbach industrial EU FP 6

Italy Ridgeback sa Paolo Barattini SME EU FP7

Italy Società Servizi Telematici srl Luigi Catarutti private non profit organisation EU Other

Italy Università Cattolica Sacro Cuore Evelina Tacconelli academic EU FP7

Italy Universita degli Studi di Milano Fransesco Blasi academic EU FP 6

Italy Universita degli Studi di Milano Nicola Principe academic EU Other

Italy Università degli Studi Verona G.Cornaglia academic EU Other

Italy Università degli studi di Firenze Paolo Bonanni academic Research collaboration

Japan Yakult Jia Zhao industrial partner Research collaboration

Latvia P. Stradins University Uga Dumpis academic EU Other

Lithuania Institute of Hygiene Rolanda Valinteliene public organisation EU Other

Lithuania Vilnius University Children Hospital Vytautas Usonis academic EU Other

Luxembourg Direction de la Santé Marcel Bruch public organisation EU Other

Malta Mater Dei Hospital Michael Borg academic EU Other

Norway Norwegian Institute Of Public Health Hege Salvesen Blix public organisation EU Other

Norway University of Oslo Morten Lindbaek academic NIH

Poland Medical University of Lodz Maciek Godyck‐Cwirko academic partner EU FP 6 & EU FP 7 & EU Other




Poland National Institute of Public Health Magdzik Wieslaw public organisation Research collaboration

Poland National Medecines Institute (NMI) Waleria Hryniewicz public organisation EU FP6 & EU Other

Portugal Associação de Saúde Infantil de Coimbra Fernando Rodrgues public organisation EU Other

Portugal Instituto de Tecnologia Quimica e Biologica Herminia de Lencastre academic EU FP 6

Portugal Instituto Nacional de Farmacia e do Medicamento Mafalda Ribeirinho public organisation EU Other

Portugal Tekever‐Technolgias de Informacao sa Lara Próspero SME EU FP7

Romania Institut for Infectious Diseases "Matei Bals" Liliana Preotescu public organisation EU FP 7

Romania National Institute of Research Development for Microbiology and Immunology Băicuş Anda public organisation EU Other

Russia Dept of Clinical Pharmacology Svetlana Ratchina public organisation EU Other

Russia St Petersburg Pasteur Institute Serge Mukumolow research Institute EU other

Serbia Clinical Centre of Serbia Biljana Jovanovic academic EU FP 7

Slovak Republic Clinical Research Associates and Consultants (CLINRAC) Zuzana Bielicka SME EU FP 6 & EU FP 7

Slovak Republic Comenius University Viliam Foltan academic EU Other

Slovenia University Medical Centre Ljubljana Milan Cižman academic EU Other

Spain Biokit sa Pau Bruguera SME EU FP 7

Spain Fundacio Clinic per a la Recerca Biomedica Antoni Torres academic EU FP 6

Spain Fundacio Privado Salut del Consorci Sanitari del Maresme Jordi Almirall academic EU FP 6

Spain Fundación para la Investigación Biomédica del Hospital Gregorio Jesus Saavedra academic EU Other

Spain Hospital Clinic i Provincial de Barcelona Antoni Torres academic EU FP 7

Spain Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Jordi Vila academic EU FP 6 & EU FP 7

Spain Instituto de Salud Carlos III, Centro Nacional de Microbiologia José Campos academic EU FP 6 & EU Other

Spain Instituto de Salud Carlos III, Centro Nacional de Microbiologia Maria Mellado academic EU Other

Spain NTE sa Jordi Carrera SME EU FP 7

Spain Universidad Politécnica de Valencia Daniel Hill academic EU FP 7

Spain Universitat de Barcelona Prof Josep Samitier academic EU FP 7

Spain University Miguel Hernandez Jesus Rodriguez Marin academic EU FP 6

Spain University of Barcelona Angela Dominguez academic EU other




Sweden Karolinska Institutet Staffan Normark academic EU FP 6

Sweden KTH ‐ The Royal Instiute of Technology Wouter van der Wijngaart academic EU FP 7

Sweden Linköpings Universitet Sigvard Mölstad academic EU FP 6 & EU FP7

Sweden Smittskyddinstitutet Birgitta H.Normark academic EU FP 6

Sweden Strama Gunilla Skoog academic EU Other

Switzerland European Respiratory Society Séverin Tania European organisation EU FP 6

Switzerland Hôpitaux Universitaires de Genève Stephan Harbarth academic EU FP 6 & EU FP7

Switzerland Lausanne University Hospital Giorgio Zanetti academic EU Other

Swizerland University Hospital Basel Heiner C. Bucher academic NIH

Switzerland University of Zurich Steffen Zeisberger academic EU FP6

Switzerland WHO Headquarters Steve Wiersma public organisation Research collaboration

The Netherlands Academical medical Center of the University of Amsterdam Lia van der Hoek academic EU FP 6

The Netherlands AMC, VU Amsterdam Ben Berkhout academic IUAP

The Netherlands Canisius Wilhelmina Hospital Joan W.Mouton public organisation EU FP 7

The Netherlands DCPrime Ada Kruisbeek industrial consultancy

The Netherlands DIAC Leiden Cees Clemens public organisation Research collaboration

The Netherlands Erasmus Universitair Medisch Centrum Rotterdam Miriam Sturkenboom academic EU Other

The Netherlands MRC ‐ Holland Jan Schouten industrial EU FP 6

The Netherlands Nijmegen Center for Molecular Life Sciences Jolanda De Vries academic clinical trials (UZA funding)

The Netherlands Pathofinder Guus Simons industrial EU FP 6

The Netherlands Radboud University, Nijmegen Medical Center Stephanie Natsch academic EU Other

The Netherlands Universiteit Maastricht Ad Masclee academic Research collaboration

The Netherlands University Medical Center Leiden Alexander Gorbalenya academic EU FP 6

The Netherlands University Medical Centre Utrecht Theo Verheij academic EU FP 6, NIH

The Netherlands University Medical Centre Utrecht Marc Bonten academic EU FP 6 & EU FP 7

The Netherlands University of Maastricht Gerard Bos academic Research collaboration

The Netherlands University Twente Albert van den Berg academic EU FP 7




Turkey ESCMID Murat Akova international public organisation EU FP 6

Turkey Haceteppe University Serhat Unal academic partner EU Other

Turkey National ref lab influenza Selim Badur academic Research collaboration

UK Acolyte Biomedica Ltd Steve O'Hara industrial EU FP 6

UK Cardiff University David Price academic Research collaboration

UK Cardiff University Christopher C.Butler academic EU FP 6, NIH

UK City University London, Health Protecting Agency Peter Borriello academic EU Other

UK Ely Bridge Research Ltd Peter Edwards industrial EU FP 6

UK Farfield Group Ltd Gerry Ronan SME EU FP 7

UK Health Protection Agency Ben Cooper public organisation EU FP 6

UK Imperial College London David Holden academic EU FP 6

UK London School of Enconomics Marieke Huysentruyt academic Research collaboration

UK London School of Hygiene and Tropical Medicine Richard Smith academic EU FP 6

UK Mr Trevor Lewis Trevor Lewis SME EU FP 7

UK St George's University of London Michael Sharland academic EU Other

UK University Cambridge David Klenerman academic EU FP 7

UK University College London Hans Stauss academic Research collaboration

UK University of Birmingham Joanna Coast academic EU FP 6

UK University of Dundee Peter Davey academic EU Other

UK University of Nottingham Roger Finch academic EU FP 6

UK University of Oxford Adrian V.S.Hill academic EU FP 6

UK University of Southampton Paul Little academic EU FP 6

USA Medstar Research Institute Nawar Shara public organisation NIH

USA Georgetown University, Washington Daniel Merenstein academic NIH

USA Washington University, St.Louis Jane Garbutt academic NIH

USA University of Wisconsin, Madison David Rabago academic NIH


37

These strategic collaborations ensure access to other equipment and scientific resources not readily available at the Consortium. In addition, they create possibilities for the mobility of researchers. The newly appointed research and innovation manager will play an important role not only in fostering existing collaborating, but also in setting‐up new ones. In case new collaborations are set‐up, the research and innovation manager will closely collaborate with the Interface Services at UA and UH to ensure contracts that safeguard the scientific work and provide sufficient remuneration. Also, possibilities in terms of technology transfer will be closely monitored. A detailed overview of projects is available in Tables 7.1‐7.4.

6.2 Ad hoc collaboration with industry Collaborating with industry has many advantages for the Consortium, such as clinical trial contract research, grants for research and access to specialised services. In the present research environment, collaboration with industry is unavoidable, and in some cases also a must, although we do bear in mind that this collaboration should not jeopardize the academic value and perception of the scientific work performed by the researchers. The long experience of the research groups with contracts and sponsoring from industry has led to the development of a policy to safeguard scientific independence with carefully negotiated contracts and with an emphasis on unrestricted grants and disclosure of conflicts of interest, if required. Currently ongoing industrial collaborations:

• AML • Baxter (through CRO PPD and CRO Harrison) • BT Pharma • Crucell • GSK Biologicals • Innogenetics • Merck • Nanopass • Nobilon‐Schering Plough • Novartis • Novartis Vaccines Institute for Global Health • Pfizer • SP • SP‐MSD • Wyeth • Yakult

A detailed overview of projects is available in Tables 7.1‐7.4. Also future collaborations will have to be clearly structured, with the required guarantees for independent scientific work. The research and innovation manager will closely collaborate with the Interface Services at UA and UH to ensure contracts that safeguard the scientific work and provide sufficient remuneration. Also, possibilities in terms of technology transfer will be closely monitored. Importantly, these ad hoc collaborations could lead to long‐term strategic collaborations with industrial partners.


38


Please note that the information presented in Figures 7.2‐7.9 and Tables 7.1‐7.3 was provided by ADOC (Dept of Research at UA), Vaxinfectio cannot be held responsible for possible errors.

39

7 External Research Funding

7.1 Overview of submitted projects 20082009 EU‐FP7 (HEALTH calls 2008)

• APRES – the appropriateness of prescribing antibiotics in primary care in Europe with respect to antibiotic resistance (Coordinator: F. Schellevis, Netherlands Institute for Health Services Research –NIVEL, The Netherlands; partner UA – Herman Goossens): collaborative project on appropriateness of prescribing antibiotics in primary care throughout Europe.

• SATURN – Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt bacteria (Coordinator: S. Harbarth, University Hospital of Geneva, Switzerland; partner UA – Herman Goossens): collaborative research project on the impact of antibiotic use on acquisition, selection and transmission of antimicrobial resistance.

• IATRICS – Intercontinental Antibiotic Trends in Resistance Initiative and Comprehensive Surveillance network – (Coordinator: Timothy Walsh, Cardiff University, UK; Partner UA – Herman Goossens): Large Scale Collaborative project addressing the problem of antimicrobial resistance at a holistic and longitudinal level – not granted

• PATRICE – Point‐of‐care diagnostics to optimise Antibiotic Treatment decisions and reduce Resistance In the Community in Europe: roadmap for effective research, development and efficient uptake (Coordinator C. Butler, Cardiff University, UK; Partner UA – Herman Goossens): Collaborative project on identifying and filling major gaps in the evidence base concerning microbial detection and antibiotic susceptibility determination – not granted

• INCOVAC – Increase Coverage of Vaccination (Coordinator Pierre Van Damme, UA): Collaborative project – not granted

EU‐IMI (call 2008) • MODULAR – Modular patient reported Outcome Design for Understanding chronic

obstructive Lung disease And intervention Response (Coordinator: C. Butler, Cardiff University, UK; Partner UA – Samuel Coenen) – not granted

IOF Postdoctoral Fellowship (Submitted: Mar 31, 2008) • Multidisciplinary research on vaccination and infectious diseases – Promotor: Prof. Dr. P. Van

Damme BOF Academiseringprojecten (Submitted: Apr 14, 2008)

• Prof. Dr. Pierre Van Damme & Prof. Dr. Marianne Stranger (Ontwerp van een didactisch model voor aanleren van correcte injectietechniek bij vaccineren) – not granted

BOF Kleine projecten (Submitted 2008) • Dr. Surbhi Malhotra. Evidence for a novel efflux pump mediating telithromycin resistance in

macrolide‐resistant Streptococcus pyogenes Hercules Large Scale Infrastructure (Submitted: 24 May 2008)

• Seeing more by looking at less: a FAIMS‐LTQ‐Orbitrap mass spectrometer platform for interdisciplinary and translational research (Prof. Dr. H. Goossens/S. Malhotra) – Not granted

IWT doctoral fellowships (Submitted: Sept 2008) • Activation of dendritic cells and natural killer cells by leukemia cells loaded with Toll‐like

receptor ligand: development of a new generation of leukemia – Promotor: Prof. Dr. Z. Berneman

• Induction of multiple sclerosis specific immune toleration using tolerogene dendritic cells and regulatory T cells. Preclinical evaluation of the therapeutic potential of cellular immune therapy in MS – Promotor: Prof. Dr. V. Van Tendeloo

Medical Legacies (Submitted: Nov 12, 2008)

- External Research Funding -

40

• Prof. Viggo Van Tendeloo (Induction of multiple sclerosis (MS)‐specific immune tolerance using tolerogenic dendritic cells and regulatory T cells)

TOP BOF (Letter of intent submitted Dec 1, 2008) • Prof. Dr. Viggo Van Tendeloo (Clinical and preclinical research of the effect of cellular

mediators on the modulation of pathogenic responses in multiple sclerosis) NOI (Submitted: Dec 8, 2008)

• Prof. Dr. Viggo Van Tendeloo (Induction of multiple sclerosis (MS)‐specific immune tolerance using tolerogenic dendritic cells and regulatory T cells) – not granted

FWO‐Krediet aan Navorsers • Dr. Surbhi Malhotra (Elucidating antibiotic resistance mechanisms mediating high‐level

resistance to ketolides and fluoroquinolones in Streptococcus pyogenes (2009‐2011)) SBO (Submitted: January 2009)

• Prof. Dr. Herman Goossens and Dr. Surbhi Malhotra (COMBIOFILM: Novel Combinatorial Strategies Targeting Biofilms) – Not granted

FWO Postdoctoral Fellowships (Submitted Feb 2009) • Evidence‐based management in primary care: the case for respiratory tract infections –

Promotor: Prof. Dr. H. Goossens – not granted • Duration of vaccine‐induced protection against hepatitis B: detailed mathematical modelling

of long‐term data vaccinated persons, evaluating the influencing factors and the correlation between humoral and cellular immune responses – Promotor: Prof. Dr. P. Van Damme – not granted

Flemish Government Intiative (Submitted: March 2009) • Prof. Dr. Herman Goossens / Dr. Surbhi Malhotra (Health care Enabled by Lightwave

Integrated Circuits in Silicon (HELICS), The Interdisciplinary Center for Silicon Biophotonics) FWO‐Onderzoeksprojecten (Submitted: April 2009)

• Prof. Dr. Herman Goossens / Dr. Surbhi Malhotra (Identification of novel surface‐expressed factors mediating virulence and biofilm formation in methicillin‐resistant Staphylococcus aureus)

• Prof. Dr. Herman Goossens / Dr. Surbhi Malhotra / Dr. Samuel Coenen (Impact of moxifloxacin and levofloxacin use on the nasal, oropharyngeal and gastro‐intestinal flora of nursing home residents) – Not granted

EU‐DG Sanco (Submitted: May 25, 2009) • ARPEC – Antibiotic Resistance and Prescribing in European Children (Coordinator: M.

Sharland, ESPID, UK; Partner UA – Herman Goossens): project on improvement of the quality of antibiotic prescribing for children in Europe and to reduce the prevalence of antimicrobial resistance in bacterial infections in children.

TOP BOF (2nd round application submitted: May 25, 2009) • Prof. Dr. Viggo Van Tendeloo (Clinical and preclinical research of the effect of cellular

mediators on the modulation of pathogenic responses in multiple sclerosis – not granted EU‐ECDC (Submitted: June 3, 2009)

• Surveillance of Hepatitis B and C (Prof. P. Van Damme) Charcot Research Fund (Submitted: Oct 15, 2009)

• Prof. Dr. Zwi Berneman (Characterization of circulating dendritic cells (DC) in multiple sclerosis (MS): evaluation of subtypes and functionality)

FWO WOG (Submitted: Oct 15, 2009) • Prof. Dr. Zwi Berneman (Multiple Sclerosis, a multidisciplinary approach)

ESF – Research Networking Programme (RNP) (Submitted: Oct 23, 2009) • TRACE – Translational Research on Antimicrobial resistance and Community‐acquired

infections in Europe (Samuel Coenen, Katherine Loens, and Herman Goossens) NIH Planning Grant (Submitted: Oct 30, 2009)

• Prof. Dr. H. Goossens (Treatment of acute rhinosinusitis)



41

BOF kleine projecten (Submitted: Nov 16, 2009) • Dr. Katherine Loens & Elke Leuridan (Maternele immuniteit in het puerperium) • Dr. Sibyl Anthierens & Dr. Samuel Coenen (Proces analyse van een internationaal interventie

onderzoek in de huisartsenpraktijk: kwalitatief onderzoek naar determinanten van het succes van een webinterventie en near patient test (CRP test) bij lage luchtweginfectie)

• Dr. Evelien Smits (In vivo niet‐invasieve beeldvorming van acute myeloide leukemie (AML) immunotherapie bij muizen)

• Dr. Nathalie Cools (Characterization of circulating dendritic cells (DC) in multiple sclerosis (MS): evaluation of subtypes and functionality)

EU‐ERC (Submitted: Nov 18, 2009) • SMILER – Simulation Models of Infections Linked with Economic Research ERC Grant (Prof.

Dr. Philippe Beutels) VLIR (Submitted: Nov 30, 2009)

• Prof. Dr. Bob Colebunders & Prof. Dr. Herman Goossens (Institutional University Cooperation Partnership with the University of Limpopo (South Africa))

NOI (Submitted: Dec 7, 2009) • Prof. Dr. Viggo Van Tendeloo (Clinical and preclinical research of the effect of cellular

mediators on the modulation of pathogenic responses in multiple sclerosis) • Dr. Peter Ponsaerts (Neural stem cells: molecular and physiological control of in vivo

differentiation, migration and immunogenicity) GOA (Letter of Intent submitted: Dec 14, 2009)

• Prof. Dr. Viggo Van Tendeloo in collaboration with the Department of Immunology, Allergology and Rheumatology (Effect of immune modulating treatments on T cell polarizing capacity of DC)

• Prof. Dr. Herman Goossens and Dr. Surbhi Malhotra in collaboration with LMPH (Prof. Drs Louis Maes and Paul Cos) and Laboratory of Protein Chemistry (Prof. Dr. Sylvia DeWilde) (Elucidation of the role of mono‐ and polymicrobial biofilms as a major cause of therapeutic failure in intensive care units (ICU): an in vitro and in vivo study of ‘biofilm’ virulence factors)

EU‐FP7 (HEALTH calls 2009) • BREATHE ‐ Biomarkers that diagnose REspiratory infection for Advanced THErapy

(Coordinator: J. Van Dissel, LUMC, The Netherlands; Partner: UA – Herman Goossens): Collaborative project on development of diagnostic markers

• SCALA ‐ Specific Cellular Anti‐Leukemia Antigen (SCALA) Therapies for Patients with Hematological Malignancies (Coordinator M. Schmitt, University of Rostock, Germany; Partner: UA – Viggo Van Tendeloo & Zwi Berneman): Large Integrated Project on cell‐based therapy

EU‐FP7 (NMP call 2009) • INDUCELL ‐ Integrating engineered and biologically derived components with a novel

automatic device for industrial cell engineering (Coordinator C. Planck, Technischen Universität München, Germany; Partner: UA – Viggo Van Tendeloo & Zwi Berneman): focused research project on validation of Magselectofection technique

WHO • Vaxinfectio: request for recognition as WHO Collaborating Center

7.2 Overview of granted projects 20082009 According to audit report from the Consultancy Company McKinsey Vaxinfectio was identified as a company spearhead, to use their terminology. According to them Vaxinfectio has potential to set‐up additional industrial collaborations thereby improving the 4th flow of money. Furthermore, Vaxinfectio was shown to obtain the highest budget in terms of industrial funding at the University of Antwerp, thereby ranking the Faculty of Medicine first not only at UA, but also when compared to


the Faculty of Medicine at UGent and KuLeuven. Figure 7.1 External funding (M€) obtained by Vaxinfectio (Source: McKinsey Company)

Figure 7.2 Overall Number of projects Vaxinfectio 2007‐2009 split by type of funding



Figure 7.3 Overall obtained budget (M€) Vaxinfectio 2007‐2009 split by type of funding

In contrast to the report by the McKinsey Company in which the amount of external funding obtained by Vaxinfectio in 2008 was mentioned to be €6.8M, the total external funding according to our data amounted to almost M€20 in 2008. Figure 7.4 Number of projects LEH 2007‐2009 split by type of funding


Figure 7.5 Obtained budget (M€) LEH 2007‐2009 split by type of funding

Figure 7.6 Number of projects LMM 2007‐2009 split by type of funding



Figure 7.7 Obtained budget (M€) LMM 2007‐2009 split by type of funding

Figure 7.8 Number of projects CEV 2007‐2009 split by type of funding


Figure 7.9 Obtained budget (M€) CEV 2007‐2009 split by type of funding

Figure 7.10 Number of projects CenStat 2007‐2009 split by type of funding



Figure 7.11 Obtained budget (M€) CenStat 2007‐2009 split by type of funding


Table 7.1 Projects LEH

Project Title Acronym Promotor Start date End date

Dendritic cells: biology and immunomodulation with dendritic cells Zwi Berneman 1/01/1999 31/12/2008

Gene therapy: from gene transfer to clinical applications Zwi Berneman 1/01/2002 31/12/2011

Feasibility of dendritic cell immunotherapy for cancer using the Wilms' tumor WT1 protein as a candidate universal tumor antigen Zwi Berneman 23/01/2004 22/01/2007

Preclinical design of RNA‐modified dendritic cell vaccines for cancer and HIV Zwi Berneman 1/10/2004 30/09/2007 Wilms' tumor gene mRNA‐transfected autologous dendritic cell vaccination for patients with acute myeloid leukemia in remission ‐ a pilot dose escalation study Zwi Berneman 24/12/2004 24/12/2007

Induction of immunity by dendritic cells in cancer and aids Zwi Berneman 1/01/2005 31/12/2008

Modulation of immune responses directed against allogeneic cell transplants in mouse Peter Ponsaerts 1/07/2006 31/12/2010 Characterisation of the in vitro activation conditions of anti‐leukemic T‐cells from leukemia patients using different types of antigen‐presenting cells Zwi Berneman 1/10/2006 30/09/2008

Transplantation of embryonic stem cell‐derived neural cells after spinal cord and traumatic brain injury Zwi Berneman 1/10/2006 30/09/2009

Transplantation of embryonic stem cell‐derived neural cells after spinal cord and traumatic brain injury Zwi Berneman 1/01/2007 31/12/2010

Inhibition of human immunodeficiency virus replication Zwi Berneman 1/01/2007 31/12/2011 Activation of dendritic cells and natural killer cells by leukemia cells loaded with Toll‐like receptor ligand: development of a new generation of leukemia vaccines Zwi Berneman 1/01/2007 31/12/2008 Dendritic cell vaccination against human cytomegalovirus in leukemia patients following allogeneic hematopoietic stem cell transplantation: A phase I/II study Zwi Berneman 1/01/2007 31/12/2010

A phase I/II study of therapeutic vaccination with autologous dendritic cells of HIV infected individuals under stable HAART Zwi Berneman 1/01/2007 31/12/2009

CRYo‐banking of stem cells for human therapeutic application CRYSTAL Peter Ponsaerts 1/02/2007 31/01/2010

Culture and characterization of neural stem cells Zwi Berneman 1/05/2007 1/07/2009

Cellular immunology in cancer and HIV, and multidisciplinary cell therapy and clinical studies Vigor Van Tendeloo 1/10/2007 30/09/2012

Effect of innate signals on leukemia cells for the stimulation of natural killer cells and T helper type 1‐polarizing dendritic cells Zwi Berneman 1/01/2008 31/12/2011

Mechanisms of secundary control of HIV infection after an episode of anti‐retroviral treatment Zwi Berneman 1/01/2008 31/12/2011

Functional characterisation of regulatory cell populations: in vitro induction of tolerance using dendritic cells Nathalie Cools 1/01/2008 31/12/2009

Non‐invasive imaging of migration and survival of stem cells in the brain BRAINSTIM Zwi Berneman 1/01/2008 31/12/2011

Effects of TLR ligand‐loaded leukemic cells and type I IFN on dendritic cell‐induced tumor specific T‐cell immunity Zwi Berneman 1/10/2008 30/09/2010 Stimulation of innate immune responses targeted against acute myeloid leukemia cells after exposure to Toll‐like receptor ligands, in view of the development of a leukemia vaccin Vigor Van Tendeloo 13/10/2008 12/10/2009

Becton Dickinson FACSAria II: highspeed, fixed alignment benchtop cell sorter platform Zwi Berneman 19/12/2008 18/12/2013

Clinical and preclinical research on the effect of cellular mediators on the modulation of pathogenic responses in multiple sclerosis Vigor Van Tendeloo 1/01/2009 31/12/2012



Project Title Acronym Promotor Start date End date

Characterization of immune responses against allogeneic stem cell implants in the central nervous system Peter Ponsaerts 1/01/2009 31/12/2011

Belgian multidisciplinary HIV research Zwi Berneman 1/01/2009 31/12/2013 Activation of dendritic cells and natural killer cells by leukemia cells loaded with Toll‐like receptor ligand: development of a new generation of leukemia vaccines Zwi Berneman 1/01/2009 31/12/2010 Feasibility and potency of a IL‐12‐secreting multi‐antigen dendritic cell vaccine in patients with leukemia and myeloma: a two‐center trial Zwi Berneman 1/01/2009 31/12/2010 Induction of multiple sclerosis specific immune toleration using tolerogene dendritic cells and regulatory T cells. Preclinical evaluation of the therapeutic potential of cellular immune therapy in MS Vigor Van Tendeloo 1/01/2009 31/12/2010 Characterization and modulation of microglial responses following transplantation of allogeneic bone marrow‐derived stromal cells in the central nervous system of immune competent mice Bart Tambuyzer 1/02/2009 31/12/2010

Induction of multiple sclerosis specific immune tolerance using tolerogenic dendritic cells and regulatory T cells Vigor Van Tendeloo 1/02/2009 31/07/2013

The effect of cellular mediators on the modulation of pathogenic responses in multiple sclerosis patients Zwi Berneman 1/10/2009 30/09/2012 Role of the Wilms tumor gene as biomarker for predicting leukemia relapse and for assessing efficacy of DC vaccination using WT1 mRNA‐transfected autologous dendritic cells of patients with acute myeloid leukemia Zwi Berneman 1/09/2009 31/08/2012

Neural stem cells: molecular and physiological control of in vivo differentiation migration and immunogenicity Zwi Berneman 1/10/2009 30/09/2012

Table 7.2 Projects LMM

Project Title Acronym Promotor Start Date End Date

European Surveillance of Antimicrobial Consumption II ESAC II Herman Goossens 1/02/2004 30/04/2007

Genomics to Combat Resistance against Antibiotics in Community‐acquired LRTI in Europe CT2005‐518226

GRACE CT2005‐518226 Herman Goossens 1/03/2006 28/02/2011

A randomised, placebo controlled double blind study to assess the efficacy of the probiotic dairy product Yakult on symptoms in Irritable Bowel Syndrome

Yakult IBS Pre‐test Herman Gooossens 26/09/2006 30/06/2007

A randomised, placebo controlled double blind study to assess the efficacy of the probiotic dairy product Yakult on symptoms in Irritable Bowel Syndrome Yakult IBS Herman Goossens 5/03/2007 31/12/2009

Development and dissemination of a school antibiotic and hygiene education pack and website across Europe E‐Bug Pack 2005211 Herman Goossens 15/06/2006 14/09/2009

European Surveillance of Antimicrobial Consumption ESAC ECD.556 Herman Goossens 18/05/2007 17/08/2007

Changing behavior of Health care professionals and the general public towards a More Prudent use of anti‐microbial agents CHAMP Herman Goossens 1/04/2007 31/03/2010

Changing behavior of Health care professionals and the general public towards a More Prudent use of anti‐microbial agents CHAMP Samuel Coenen 19/01/2009 31/05/2009

European Surveillance of Antimicrobial Consumption ESAC III ECD.609 Herman Goossens 3/09/2007 2/09/2008



Evidence‐based management in primary care: the case for respiratory tract infections Herman Goossens 1/10/2006 30/09/2009

Mechanisms of antibiotic resistance and tolerance and the associated fitness costs in streptococci causing respiratory tract infections Herman Goossens 1/10/2007 30/09/2010 Improving the management of lower respiratory tract infections in general practice by means of etiological, prognostic and interventional studies. Herman Goossens 1/01/2008 31/12/2011

Mastering hOspital Antimicrobial Resistance and its spread into the community MOSAR Herman Goossens 1/02/2007 31/01/2012

Integrated vaccine and infectious disease research Methusalem

Herman Goossens/Pierre Van Damme/ Zwi Berneman 1/01/2008 31/12/2014

Evidence for a Novel Efflux Pump Mediating Telithromycin Resistance in Macrolide‐Resistant Streptococcus pyogenes Surbhi Malhotra 1/01/2008 31/12/2009

An integrated platform enabling Theranostic applications at the Point of Primary Care TheraEDGE Herman Goossens 1/03/2008 29/02/2012

European Surveillance of Antimicrobial Consumption ESAC III ECD.1018 Herman Goossens 3/09/2008 2/09/2009

A highly integrated optical sensor for point of care label free identification of pathogenic bacteria strains and their antibiotic resistance Intopsens Herman Goossens 1/09/2008 31/08/2011 Elucidating Antibiotic Resistance Mechanisms Mediating High‐level Resistance to Ketolides and Fluoroquinolones in Streptococcus pyogenes Surbhi Malhotra 1/01/2009 31/12/2011

Evidence‐based management in primary care: the case for respiratory tract infections Herman Goossens 1/10/2009 30/09/2010

European Surveillance of Antimicrobial Consumtion III ECD.1702 ESAC III ECD.1702 Herman Goossens 3/09/2009 31/12/2010

The appropriateness of prescribing antibiotics in primary health care in Europe with respect to antibiotic resistance APRES Herman Goossens 1/10/2009 30/09/2013

Antibiotic Resistance and Prescribing in European Children ARPEC Herman Goossens 1/01/2010 31/12/2013

Impact of Specific Antibiotic Therapies on the prevalence of human host Resistant bacteria SATURN Herman Goossens 1/01/2010 31/12/2013

Table 7.3 Projects CEV


Support to the activities of the Viral Hepatitis Prevention Board (VHPB) Pierre Van Damme 1/01/2000 31/12/2010

Preventative health of prostitutes in Antwerp Pierre Van Damme 1/01/2002 31/12/2008 Statistical properties of the force of infection, the contact matrix and the reproduction rate estimation, interrelation and impact on mathematical models for the dynamic transmission of infectious diseases. Pierre Van Damme 1/01/2004 31/12/2009 A double blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals ‐ herpes simplex candidate vaccine (gD2 ASO4) in healthy HSV seronegative and seropositive female subjects aged 10‐17y. Pierre Van Damme 23/04/2004 30/06/2009 Improving Public Health Policy in Europe through Modelling and economic evaluation of Interventions for the Control of Infectious Diseases. POLYMOD Pierre Van Damme 1/09/2004 31/08/2008

Effective and acceptable strategies for the control of SARS and new emerging infections in China and Europe, SARSControl Pierre Van Damme 1/01/2005 31/03/2008




Transmission of material antibodies in a low endemic country Pierre Van Damme 1/12/2005 31/12/2008 Prevalence of maternal antibodies against vaccine preventable infections: sero‐epidemiological survey of antobody concentrations in woman in third trimester of pregnancy; comparison between vaccinated and mothers with natural immunity. Pierre Van Damme 1/03/2006 31/12/2007 A Open‐label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Gardasil TM Given Concomitantly with Repevax TM in Healthy Adolescents 11‐17 Years of Age. Pierre Van Damme 4/05/2006 31/05/2007

Safety and Immunogenicity of an intramuscular, inactivated, Split‐Virion, Pandemic Influenza A/H5N1 Vaccine in Adults and the Elderly. Pierre Van Damme 1/07/2006 30/06/2008 A long‐term, open follow‐up of the immunogenicity and safety of GSK HPV‐16/18/31/45 L1/AS04 vaccine in healthy female subjects vaccinated in the HPV‐TETRA‐051 study. Pierre Van Damme 31/08/2006 31/08/2009

Vaccine Safety ‐ Attitudes, Training and Communication. VACSATC Pierre Van Damme 1/09/2006 31/10/2009 Duration of vaccine‐induced protection against hepatitis B: detailed mathematical modelling of long‐term data vaccinated persons, evaluating the influencing factors and the correlation between humoral and cellular immune responses. Pierre Van Damme 1/10/2006 30/09/2009

NanoVax. Pierre Van Damme 1/03/2007 31/12/2009

Has the time to control Hepatitis A globally? Pierre Van Damme 1/06/2007 31/05/2008 A phase I, open‐label, vaccination study to evaluate the safety and immunogenecity of the GSK Biologicals recombinant CMV gB sub‐unit GSK1492903A in CMV‐seronegative healthy adult subjects. Pierre Van Damme 1/07/2007 30/06/2008 A phase I/II, observer‐blind, randomized multicentre study to assess the safety and immunogenicity of an HPV‐16/18/33/58 L1 vaccine formulated with different adjuvant systems when administered intramuscularly in healthy adult females. Pierre Van Damme 1/08/2007 31/07/2008 A Study of the Immunogenicity and Safety of an inactivated Split‐Virion Influenza Vaccine administered by Intradermal Route versus an Inactivated adjuvanted Influenza Vaccine administered by Intramuscular Route in subjects of 65 years of age or older. Pierre Van Damme 1/10/2007 31/10/2007

Creation of a translational platform for integrated vaccine research. Pierre Van Damme 1/12/2007 26/11/2012

Health Economics Research and Mathematical Modelling of Infectious Diseaeses. Pierre Van Damme 1/12/2007 30/11/2010

Study of vaccination coverage in children and adolescents in Flanders in 2008. Pierre Van Damme 1/12/2007 31/12/2008

Economic evaluation of rotavirus immunisation of infants in Belgium. Philippe Beutels 1/12/2006 31/05/2007

A phase III clinical trial to evaluate the efficacy, immunogenicity, safety and tolerability of ZOSTAVAX in subjects 50 to 59 years of age Pierre Van Damme 1/01/2008 31/05/2010 A phase IV, open, multicentre, multicountry study to evaluate the immune response to a challenge dose of GSK Biologicals Twinrix vaccine, approximately 48 months after primary vaccination Pierre Van Damme 1/01/2008 30/09/2008 Case‐control study to evaluate the vaccine effectiveness of live attenuated rotavirus vaccines against community‐acquired rotavirus severe gastroenteritis among hospitalized children born after 1 October 2006 in Belgium. Pierre Van Damme 1/02/2008 31/05/2010 A phase IV, open, multicentric study to evaluate the immune response to hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Biologicals' Engerix‐B vaccine, in the primary study HBV‐280. Pierre Van Damme 1/02/2008 1/03/2009

Clinical Study "Maternal Antibodies against Pertussis in Neonates: Natab 2 Study". Pierre Van Damme 30/04/2008 30/06/2008 An Open‐Label Phase III Study to Assess the Safety and Immunogenicity of a Vero Cell‐Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as well as in Specified Risk Group. Pierre Van Damme 1/06/2008 30/09/2009 Immunogenicity of the Investigational, Inactivated, Split‐Virion Influenza vaccine administered by the Intradermal route in comparison with the intramuscular reference vaccine Vaxigrip (c) in the elderly. Pierre Van Damme 6/06/2008 31/10/2009 A blinded phase I/II dose escalation study to assess safety and immunogenicity and investigate the optimal dose level of a formalin‐treated, uv‐inactivated, vero cell‐derived ross river virus (RRV) vaccine in healthy volunteers aged 18 to 40 years Pierre Van Damme 9/06/2008 31/03/2009


Project Title Acronym Promotor Start Date End Date A phase 1, multicenter, randomized, placebo‐controlled study ... plasmid competition and payload on the immunogenicity of a DNA influenza vaccine administered by particle mediated epidermal delivery to healthy adults. Pierre Van Damme 21/08/2008 20/08/2009

Drug use among female sex workers in Belgium. DRUSEB Pierre Van Damme 1/10/2008 28/02/2011 A double blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of inactivated hepatitis A vaccine containing 1440EI.U of antigen per ml and injected according to a 0‐12 months schedule. Pierre Van Damme 28/10/2008 31/01/2013 A double blind, randomized study to evaluate the immunogenicity and reactogenicity of two different lots of inactivated hepatitis A vaccine containing 1440EI.U of antigen per ml and injected according to a 0‐6 months schedule. Pierre Van Damme 28/10/2008 31/03/2013

What explains socio‐economic differences in health behaviour? Vaccination of Children. Cornelius Van den Bosch 1/10/2008 30/09/2010 A phase II, randomized, multicentre, observer‐blind study to ... with the Hepatitis B surface antigen (HBsAg), according to a 0,1 month schedule with a booster at month 12,in healthy, Hepatitis B virus (HBV) naïve, adults. (112115) Pierre Van Damme 1/01/2009 20/08/2010 A Rising Single Dose, Double‐Blind, Randomized, Placebo‐ Controlled Study to Evaluate Safety, Tolerability and Immunogenicity of SCH 900795 in Healthy Adults P05653‐01. Pierre Van Damme 1/02/2009 31/01/2011 A phase III, open, multi‐centre, non‐randomized, trial to evaluate the immunogenicity and safety of a two‐dose schedule of the A/California/7/2009 (H1N1)v‐like candidate vaccine manufactured in Dresden adjuvanted with ASO3A, in adults of 18 years & above Pierre Van Damme 1/08/2009 31/10/2010 A randomized, single‐blind, dose‐ranging...of adjuvanted and non adjuvanted egg‐derived inactivated novel swine rigin A/H1N1 monovalent subunit influenza virus vaccine in healthy subjects 18 or more years of age Pierre Van Damme 5/08/2009 31/08/2011 Vaccination coverage and timing of vaccination in children and adolescents in Belgium (retrospective study carried out via an internet‐based questionnaire). Pierre Van Damme 26/08/2009 25/08/2010

Surveillance of hepatitis B en C. Pierre Van Damme 6/09/2009 31/12/2009 An open, single centre study to evaluate the long‐term antibody persistence and immune memory between 16 and 20 years after the primary study HAB‐028 (208127/021) in which healthy adults were vaccinated with Twinrix Adult following a three‐dose schedule Pierre Van Damme 1/10/2009 31/10/2015

Multidisciplinary research on vaccination and infectious diseases. Pierre Van Damme 1/11/2009 31/10/2011

Scientific Chair "Evidence Based Vaccinology". Philippe Beutels 1/01/2009 31/12/2011

Infectious diseases models: wildlife ecology, ecological disturbance and transmission to humans. Herwig Leirs 1/01/2009 31/12/2012

Scientific Chair "Advanced research and development in addiction medicine & psychiatry". Bernard Sabbe 1/01/2009 31/12/2011 Contacts between children with chickenpox and varicella zoster immune adults: an analysis of the post‐exposure impact on cellular immunity. Philippe Beutels 1/01/2007 31/12/2008

Simulation models of infectious diseases transmission and control processes. SIMID Philippe Beutels 1/03/2007 28/02/2011

Standardization of Economic Evaluations. Philippe Beutels 1/03/2007 31/08/2007

Program Evaluation of universal and targeted options for use of hepatitis A vaccines in Belgium. Philippe Beutels 1/07/2007 1/09/2008

Evaluation of Crisis and Case Management. ECCAM Guido Van Hal 1/10/2008 30/04/2010

Health Economics. Philippe Beutels 1/01/2009 31/12/2013

Research project in the context of the study no.2009‐10‐HTA VZV vaccination in children and adults aged over 50 years. Philippe Beutels 1/06/2009 31/05/2010

Innovative research of pertussis specific anti‐pertactine IgG as a proxi for incident infections. Koen Van Herck 1/01/2007 31/12/2008

A study of the HBsAg specific T‐cell and B‐cell‐mediated immunity in adults, many years after hepatitis B vaccination. Koen Van Herck 1/01/2008 31/12/2010




Surveillance of invasive pneumococcal disease (IPD) in adults in Belgium: scientific advice and validation of the results. Koen Van Herck 2/11/2008 1/01/2009

Table 7.4 Projects CenStat

Project Title Promotor Start Date End Date Analysis of the EU‐wide baseline surveys on Campylobacter spp. in broiler flocks and on Campylobacter spp. and Salmonella spp. in broiler carcasses Lot No. 2 Marc Aerts 1/12/2008 1/08/2010 Beleidsgegevens over psychiatrische diensten en instellingen: permanente registratie van klinische en sociale variabelen. Overeenkomst inzake de ondersteuning van registratiesysteem: "Minimale Psychiatrische Gegevens" Marc Aerts 1/01/2009 31/12/2009

Berekening van de sample size voor de klinische studie voor AMT Herbert Thijs 22/06/2009 23/09/2009

Berekening voor de FDA meeting voor AMT Herbert Thijs 22/06/2009 23/09/2009

Biostatistical consulting for UCB Geert Molenberghs 1/01/2005 31/12/2009

Committee member agreement with Sanofi‐Aventis Geert Molenberghs 1/07/2008 31/12/2011

Consultancy Master Agreement with Mars Marc Aerts 1/08/2008 31/07/2009

Consultancy overeenkomst Geert Molenberghs 4/08/2008 4/08/2009

Consulting agreement with Schwarz Biosciences Marc Aerts 1/11/2008 31/10/2009

Consulting Agreement with Eli Lilly Geert Molenberghs 1/05/2009 30/04/2010

Consulting Agreement with Tibotec Pharmaceutical Ltd. ‐ consulting January 2009 Geert Molenberghs 1/01/2009 31/01/2009

Consulting Agreement with MARS Petcare UK Ltd Marc Aerts 7/07/2009 6/07/2010

Contract wetenschappelijke dienstverlening Marc Aerts 8/07/2008 7/01/2009

Coördinatie van wetenschappelijke dienstverlening en contractonderzoek Marc Aerts 1/01/2009 31/12/2013

Creatie MPG‐eenheidsbestanden voor SPIL Geert Molenberghs 1/01/2007 31/12/2009

Datasafety Monitoring Board with Sanofi‐Aventis Herbert Thijs 1/07/2008 31/07/2011 De analyse van gegevens verzameld binnen het PWO 'Goed Onderwijs' van de XIOS Hogeschool door STATCOM UHasselt onder de supervisie van A. Laenen Herbert Thijs 16/03/2009 15/04/2009

De bio‐informatica‐aspecten van mathematische en statistische modellen voor infectieziekten Ziv Shkedy 1/01/2007 31/12/2010 Development of a SAS macro to import, analyse and visualize data from the DG‐SANCO Rapid Alert System for Foood and Feed Savety as a tool for “early warning” Geert Molenberghs 2/12/2008 1/07/2009

Een flexibele methode voor het modelleren van niet‐normale hierarchische gegevensstructuren Geert Molenberghs 1/01/2009 31/12/2012

Een krachtig modelleringskader voor het efficiënt opzetten en analyseren van levenswetenschappelijke studies Geert Molenberghs 1/01/2009 31/12/2012

Gezamelijke vormgeving van HCV en HIV van de longitudinale (tijd‐reeks) gegevens van Italië Ziv Shkedy 11/02/2009 31/12/2009


Project Title Promotor Start Date End Date

Input voor het vervolg protocol waar de nadruk pancreatitis is Herbert Thijs 22/06/2009 23/09/2009

Internationale cursus "Master of Science in Biostatistics" Paul Janssen 1/09/2008 30/06/2009

Milieu en Gezondheid Geert Molenberghs 1/01/2007 31/12/2011 Opmaak en uitvoeren van een draaiboek voor het uitvoeren van een moedermelkcampagne voor de gevalsstudie: ' Gechloreerde verbindingen in landelijke gebieden' in het kader van een geïntegreerd faseplan. Marc Aerts 1/02/2009 31/01/2010 Overeenkomst voor de implementatie van een samenwerkingsproject in kader van het Noord‐Zuid‐samenwerkingsprogramma (NSSCP) van de institutionele universitaire samenwerking tussen Universiteit Hasselt, Jimma University (JU), Ethiopia and University Eduardo Mondlane (UEM), Mozambique ‐ R 1942 Marc Aerts 1/04/2009 31/03/2011

Personeelsdatabank Marc Aerts 19/01/2009 31/12/2009

Project Title: " Solving the interpretation versus misspecification dilemma in psychological, social and behavioral measurements" Geert Molenberghs 31/08/2008 31/08/2009

Project Title: " Solving the interpretation versus misspecification dilemma in psychological, social and behavioral measurements" Geert Molenberghs 31/08/2009 31/08/2010 Samenwerking in het kader van de voorbereiding van een Vlaams Supercomputer Centrum voor publiek en privaat gefinacierd onderzoek Paul Janssen 23/05/2008 23/05/2009 Schatting van het onderwerp heterogeniteit, co‐infectie en de gezamenlijke ontwikkeling van modellen van HCV, HBV en HIC uit Cross‐sectionele serologische gegevens Ziv Shkedy 11/02/2009 31/12/2009

Schatting van infectieziekte‐parameters gebaseerd op mixture modellen Ziv Shkedy 1/10/2008 30/09/2010

Semi‐parametrische Cox’s regressie modellen voor multivariate, links‐gecensureerde overlevingsdata met extra nullen Roel Braekers 1/10/2009 30/09/2011 Simulatiemodellen voor overdracht van besmettelijke ziekten en controleprocessen, met toepassing op de vijf grote gezondheidstopics vanuit het Vlaamse beleid Marc Aerts 1/03/2007 31/12/2011

Statistische analyse voor Pronota Geert Molenberghs 27/01/2007 26/01/2009

Statistische analyse van associatie en afhankelijkheid in complexe data Noel Veraverbeke 1/01/2007 31/12/2011

Statistische analyse van isotoop‐gemerkte MALDI‐TOF massa spectra Tomasz Burzykowski 1/01/2009 31/12/2012

Statistische analyses "'Jongeren met een rugzak ... 't werkt" Geert Molenberghs 10/06/2006 30/09/2009 Statistische eigenschappen en impact van onvolledige gegevens op de analyse van spatio‐temporele modellen voor de ruimtelijke en temporele dynamica van infectieziekten Noel Veraverbeke 1/10/2007 30/09/2010 Statistische eigenschappen van de infectiedruk, de contractmatrix en de reproductiesnelheid: kwantificering, onderlinge wisselwerking en impact in mathematische modellen voor de dynamische transmissie van infectieziekten Marc Aerts 1/01/2004 31/12/2009 Statistische verwerking en ondersteuning in het kader van het onderzoek naar het huidige blootstellingsniveau aan zware metalen in de Noorderkempen Geert Molenberghs 1/11/2006 31/12/2009

Wetenschappelijke dienstverlening in kader van experiment 1051: Taminco Marc Aerts 1/07/2009 31/07/2009

Wiskundige en statistische methode voor bacteriologische risico vaststelling en besmettelijk ziektemodel Marc Aerts 4/05/2008 31/03/2009

Work Order in functie van het IWT (n° 80536) project "Cell Line based compound prioritization and response prediction" Marc Aerts 1/12/2008 30/11/2010

Analyse uitvoeren en draft papers schrijven Ziv Shkedy 1/07/2007 30/09/2007

Analyseren van veiligheidsdata: EPO‐ANE‐4008 Bestuurs Commissie Vergaderingen Oktober 2008 Herziening van documenten Geert Molenberghs 1/10/2008 31/10/2008



Project Title Promotor Start Date End Date

Bewezen diensten aan DSMB in functie van het TMC114‐C229 onderzoek: December 2008 Herziening van het rapport Geert Molenberghs 1/12/2008 31/12/2008 Bijstand bij de statistische analyse van baseline enquetes rond het voorkomen en de risicofactoren van Salmonella in slachtvarkens en kalkoenen Marc Aerts 20/12/2007 31/10/2008

Consultancy Agreement Geert Molenberghs 27/04/2006 27/07/2007

Consultancy Agreement Herbert Thijs 27/04/2006 27/04/2007

Consultancy service Geert Molenberghs 15/09/2006 14/09/2007

Consulting juli 2008 Consulting Overeenkomst dd. 27/04/2005 Geert Molenberghs 1/07/2008 31/07/2008

Consulting november 2008 Consulting Overeenkomst dd. 27/04/2005 Geert Molenberghs 1/11/2008 30/11/2008

Consulting oktober 2008 Consulting Overeenkomst dd. 27/04/2005 Geert Molenberghs 1/10/2008 31/10/2008

Consulting september 2008 Consulting Overeenkomst dd. 27/04/2008 Geert Molenberghs 1/09/2008 30/09/2008

Convention Marc Aerts 1/07/2008 31/12/2008

Flexibele wiskundige en statistische modellen voor microbiologische risicobeoordeling Geert Molenberghs 1/01/2005 31/12/2008

Geavanceerde statistische modellen voor de risico‐analyse van toxicologische studie in de farmaceutische industrie (type 3) Marc Aerts 1/04/2005 31/03/2007

Improving public health policy in Europe through Modelling and Economic Evaluation Marc Aerts 1/07/2004 30/06/2008

Internationale cursus "Master of Science in Biostatistics" Paul Janssen 1/09/2007 30/06/2008

Intra‐ en inter‐individuele variaties bij key biomarkers binnen een algemene populatie Geert Molenberghs 15/03/2006 31/03/2008 Onderaannemingscontract ‐ Beleidsgegevens over psychiatrische diensten en instellingen: permanente registratie van klinische en sociale variabelen. Onderzoeksovereenkomst inzake de ontwikkeling van registratiesystemen. Marc Aerts 1/01/2008 31/12/2008

Ondersteuning van het registratiesysteem 'Minimale Psychiatrische Gegevens (0.5 VTE) Annouschka Laenen 1/01/2008 31/12/2008 Ontwikkeling van een methodologie voor de kwantitatieve beoordeling van zoönotische risico's in België toegepast op het model Salmonella bij varkens Marc Aerts 1/12/2004 30/11/2007

Project title: " Solving the interpretation versus misspecification dilemma in psychological, social and behavioral measurements" Geert Molenberghs 1/09/2007 31/08/2008

Statistische analyses Geert Molenberghs 15/03/2006 14/03/2008







Statistische dienstverlening Geert Molenberghs 14/06/2006 19/08/2008


Project Title Promotor Start Date End Date Statistische ondersteuning en verwerking van de resultaten van het onderzoek naar het huidig blootstellingsniveau aan zware metalen rond Hoboken Marc Aerts 1/01/2008 31/12/2008

T‐bedden in psychiatrie: Studie over langdurige psychiatrische opnames Geert Molenberghs 15/10/2006 30/11/2007

VLIR‐UOS Beurzentoekenningsprogramma Uhasselt Paul Janssen 1/01/2008 31/12/2008

Wetenschappelijke dienstverlening Geert Molenberghs 5/11/2007 31/12/2008



57

7.3 Project proposals in the pipeline 20102011 BOF ID‐Scholarships (Deadline for submission: Jan 11, 2009) Philippe Beutels (CEV) & Guido Van Hal (ESOC) Peter Ponsaerts (LEH) & Annemie Schuerwegh (Immunologie) FWO Scholarships (Deadline for submission: Feb 1, 2010) Herman Goossens & Surbhi Malhotra (LMM) EU Innovative Medicines (IMI) (Deadline for submission: Feb 8, 2010) IWT‐TETRA (Deadline for submission: Feb 8, 2010) Artesis and CEV IWT Baekeland (Deadline for submission: Feb 26, 2010) BioMaric and LEH FWO Onderzoeksprojecten and KAN (Deadline for submission: April 1, 2010) Herman Goossens & Surbhi Malhotra (LMM) GOA (Letter of intent submitted: 2009)

Herman Goossens & Surbhi Malhotra (LMM), Louis Maes & Paul Cos (LMPH), and Sylvia Dewilde (Protein Chemistry Lab)

7.4 Difficulties encountered with obtaining additional funding The leading researchers of the Consortium at UA have encountered problems with applying for internal BOF funding, including GOA, NOI, and BOF kleine projecten, as these projects, according to internal UA regulation, do not allow submission by a promotor who already has been granted Methusalem Funding or is promotor of a Center of Excellence. This policy is however only pursued by the University of Antwerp, whereas this is not the case for other Universities, including the partner University within this Methusalem Consortium, Hasselt University. This UA policy contradicts Article 14 undies of the Flemish Government Directive which states that ‘Methusalem Funding does not exclude researchers from applying for additional funding, in particular funding from sources mentioned under Article 1bis’. It should be noted that Article 1bis refers to BOF resources (see Annex IV). Next to BOF funding, the Consortium forsees problems with future FP7, DG Sanco and other EU grant applications. Too few permanent staff is currently employed within the consortium thereby jeopardizing future grant applications for FP7, which require an input of permanent staff next to staff employed by the project. The University of Antwerp decided to limit the percentages of permanent staff to be employed for FP7 projects to 20% for ZAP, 5% for AAP and ATP. Next to FP7, DG Sanco and other EU grants require the input of co‐funding of 10% up to 60% which is to be financed through the input of once again permanent staff. The University decided to limit the percentages of permanent staff to be employed for these projects to 20% for ZAP, 50% for AAP and ATP. These rules combined with the shortage of permanent employed within the consortium makes future applications virtually impossible based on the current track record of EU projects submitted or in the pipeline as well as ongoing (see 7.1 and 7.2).


58


8 Human Resources

8.1 Overview of Methusalem Personnel The scientific expertise and excellence of the Consortium, grouping about 120 staff members, is entrenched in four research units (Laboratory of Medical Microbiology, Centre for the Evaluation of Vaccination, Laboratory of Experimental Hematology, Center for Statistics) and their leading researchers, Prof. Dr. Herman Goossens (Laboratory of Medical Microbiology, LMM), Prof Dr. Pierre Van Damme (Centre for the Evaluation of Vaccination, CEV), Prof. Dr. Philippe Beutels (Centre for health economics and Modelling & Infectious Disease Modelling), Prof. Dr. Zwi Berman (Laboratory of Experimental Hematology, LEH), Prof. Dr. Viggo Van Tendeloo (Centre for Cell Therapy en Regenerative Medicine, CCRM), Prof. Dr. Geert Molenberghs, Prof. Dr. Marc Aerts, and Prof. Dr. Ziv Shkedy, Prof. Dr. Niel Hens (Center for Statistics, CenStat). The number of staff employed within the Methusalem has increased with 27 staff members from 2007 to date. Currently, 121 staff members are employed in the consortium of which 85 at UA and 36 at UH. Within Vaxinfectio, 32 staff members belong to LMM, 28 to CEV and 25 to LEH. The division by personnel category at the start of the Methusalem Funding is given in Figure 8.1 and the current division (2009) in Figure 8.2. Figure 8.1 Personnel by category 2007 (n=90)

11

34

14

9

22

ZAP

BAP pre‐doc

BAP post‐doc

AAP

ATP

- Human Resources -

Figure 8.2 Personnel by category 2009 (n=121)

Annex V provides a list of staff members currently employed within the Methusalem Consortium. The Consortium applies, to the maximum extent possible, the university’s policy for equal opportunities; hence gender equality principles are being applied in the personnel policy of the Consortium. In 2007, almost 60% (53 out of 90) of the staff was female of which almost 75% (39 out of 53) belonged to the academic personnel (1 ZAP, 5 postdocs and 33 predocs). Although the number of women employed within the Consortium slightly decreased in 2009 to 55% (67 out of 121) of which 67% (45 out of 67) belonged to the academic personnel, there were more women in higher poistions (2 ZAP, 11 postdocs and 32 predocs).

8.2 Opportunities for Postdoctoral Researchers Due to its relative size, the Consortium tries to offer career opportunities and perspectives for young researchers, as well as a career perspective to more established researchers. The Methusalem Consortium was in terms of gender equality able to offer career perspectives for women. From 2007 to now, one postdoc was promoted to ZAP and 6 employees were offered a postdoc position. Vaxinfectio applied for a managerial position in 2008 and in 2009 such a position was offered at the University of Antwerp to recruit an IOF (Industrial Research Fund) manager for Vaxinfectio. This position was recently taken up by a junior female postdoc after a successful defence at the Board for Industrial Research and Innovation. The Consortium plans to invest in proper and suitable training and guidance for their young predoctoral researchers by postdoctoral researchers. Also, specific training and education needs will be identified and incorporated as much as possible for each individual staff member. Nevertheless, additional funding and career perspectives by the University of Antwerp are needed to enable sufficient long‐term perspectives. This includes establishing middle management opportunities for post‐doc researchers at UA. An ERC (European Research Council) grant application for senior researchers has been submitted in 2009 by Prof Dr Philippe Beutels who is since September 1, 2009 employed as ZAPBOF within the


Vaxinfectio Consortium. Based on the established reputation of the Consortium, we plan to attract additional specific funding schemes for well‐sponsored scholarships, such as the Flemish Odysseus programme, i.e. the federal grants for returning researchers, and the starting and advanced independent researcher grants from the ERC.

8.3 PhD students & PhDs obtained In 2007, a total of 43 PhD students were employed within the Consortium. This number further increased to 58 in 2009. Figure 8.3 gives an overview of the PhD students in 2007 vs 2009. Figure 8.4 clearly shows that all newly recruited PhD students are being paid through external funding. To date, 2 PhDs (Evelien Smits and Vanessa Vankerckhoven) have been obtained within the Consortium. We expect that 21 PhDs will be obtained during the next 2 years (2010‐2011) of which 3 at CEV (H. Theeten, E. Leuridan, B. De Vos), 7 at LMM (B. Michiels, C. Vael, P. Zarb, N. Adriaenssens, P. McNeil, B. Amadeo, L. Van Heirstraeten), 5 at LEH (A. Van Driessche, E. Lion, A. Van de Velde, I. Bergwerf, K. Reekmans), and 7 at UH (A. Gaddah, A. Kasim, P. Haldermans en Q.A. Zhu, A. Creemers, N. Goeyvaerts, S. Pramana). Figure 8.3 PhD Students 2007‐2009

- Human Resources -

Figure 8.4 External vs UA funding of PhD students


63

9 Budget & Investments

9.1 Overall budget 20082014 3.453.079 EUR (incl.10% overhead) for the University of Antwerp part, and 1.726.540 EUR (incl. 10% overhead) for the Hasselt University part. Thus, for the period 2008‐2014, the total Methusalem budget amounts to 5.179.619 EUR.

9.2 Budget Vaxinfectio The resources of the Methusalem programme are considered as a continuous basic investment fund in support of ongoing and future research. Next to Methusalem Funding, the Consortium has also applied for additional external and internal funding (see heading 5: External Research Funding) and will continue to apply for resources in terms of projects and scholarships from traditional research funding agencies such as BOF, FWO, IWT, EU and others, to complement or increase the Methusalem funding. A central operational budget has been set aside to strengthen the collaboration among the participating research teams, and to develop new common collaborations with other teams in and outside the consortium and the 2 universities. The remaining budget at UA has been divided equally among the three leading research groups, as to provide them with a minimum of means to implement their research activities.

Investments in expert personnel 20082009 CEV has recruited expert personnel for vaccine study coordination and improvement of internal quality of vaccine studies (e.g. drafting SOPs) as well as for translational research in collaboration with the industry. LMM has recruited 3 additional technicians to conduct the experimental work for the newly granted and ongoing EU and non‐EU projects, as well as 2 additional administrative staff members to manage the administrative work and finances for each of these newly granted and ongoing projects. A total of 4 PhD students (3 Dehousse and 1 AAP) have been recruited, among which also one AAP who will be in charge of education and practical courses for medicine students and students biomedical sciences. Within the ESAC project two joint PhD was set‐up for 2 PhD students, i.e. collaboration with the University of Bordeaux, France and Queens University of Belfast, Ireland. All PhD students are working on a PhD thesis of which the topics are in line with the newly granted EU and non‐EU projects. Also, one post‐doc was recruited. LEH has recruited 3 additional lab technicians to conduct the experimental work for the analysis of cellular immunity in longitudinal vaccine trials performed by CEV as well as for the preparation of therapeutic DC vaccines in cancer patients. Also, they recruited 3 new PhD students active on the topic of cellular immunity or stem cell immunology.

Investments in stateoftheart technologies, methodologies and equipment 2008

2009 It is obvious that an investment in the latest available technologies and equipment is a must, if the Consortium wishes to remain in the forefront of academic research. The investments in specific equipment have been determined by the ongoing and future research topics. The Methusalem funding made investment in specific equipment possible:

- Budget & Investments -

64

EQUIPMENT at LEH 1. Liquid Nitrogen Container (Linde Gas Cryoservices; 27.149,98 EUR (excl. TVA)) Main purpose: Long time storage and preservation of viable blood‐derived cells 2. BD FACSAria II flow cytometric cell sorter (Becton Dickinson; 352.764,00 EUR (excl. TVA)) The instrument was purchased by applying for external funding provided by the Hercules programme. Description: BD FACSAria II is a flow cytometric cells sorter, equipped with 3 lasers (488 nm, 633 nm and 405 nm), capable of measuring 15 different parameters simultaneously. Using flow cytometric cell sorting, one is able to sort a predefined cell subset out of a heterogenous population, e.g. blood. In this case, a multiparametric approach is often the only way to separate cells based on the expression of various markers (up to 12) concurrently. Main applications: After flow cytometric cell sorting, we are able to study a variety of properties, characteristics and/or functions of sorted cell populations:

• Sorting of cells transfected with reporter genes: e.g. Transfection of cells with silencing RNA (siRNA) results in downregulation of respective protein expression. Cotransfection with GFP enables us to isolate GFP‐positive cells and study protein function.

• Cell culture and cloning: Single cell cloning is a feasible application using cell per cell sorting in multiwell plates.

• Study of DNA: Using flow cytometric cell sorting, we are able to isolate malignant cell populations out of blood, bone marrow or patient biopsies, in order to further investigate chromosomal aberrations using FISH or PCR.

3. Microscope (Olympus; 40.000,00 EUR (excl. TVA)) The Laboratory of Experimental Hematology used Methusalem funding to co‐finance (50%, i.e. 20.000 euro) with the Laboratory of Pathology (Prof. Eric Van Marck) a new Olympus BX51 fluorescence microscope equipped with an Olympus DP71 digital camera. This equipment supports Prof. Berneman & Dr. Peter Ponsaerts’ neuro‐immunology research on understanding and modulating the brains innate immune responses against allogeneic stem cell transplants and glioblastoma in rodents. Photograpical images taken using this novel microscope will be printed in several publications currently in preparation. EQUIPMENT at LMM Real‐Time PCR (StepOnePlus, Applied Biosystems; 29.982,30 EUR (excl TVA)) A real‐time PCR intrument was bought by LMM using Methusalem funding to co‐finance (13.453,4 EUR) with two major aims: 1) To quantify a differential expression of antibiotic resistance genes, especially those mediating macrolide and ketolide efflux in clinical strains of Streptococcus pyogenes, 2) To quantify differences in capsule production between the parent S. pyogenes strains and the in vitro selected high‐level fluoroquinolone resistant mucoid mutants that we have generated in our laboratory. All equipment is available for use by all members of the Consortium.


65

Future Investments in stateoftheart technologies, methodologies and

equipment For the planned shift of LMM to the 6th floor of Building S, the Methusalem funding will be used to invest in laboratory equipment, which will lead to not only optimatisation of the labs and an improvement of their competitive position, but will also enable accreditation of the laboratory of Medical Microbiology.

9.3 Budget CenStat CenStat considers the Methusalem funding a continuous reseach fund. The CenStat budget is used to fund predoctoral positions focusing on statistical methodology within the collaboration with all research partners at UA. In addition, a postdoctoral position, overseeing the collaboration between CenStat and Vaxinfectio is funded. Next to the Methusalem funding, CenStat continuously applies for additional external and internal funding and will continue to apply for resources in terms of projects and scholarships from traditional research funding agencies such as BOF, FWO, IWT, EU, and others, to complement or increase the Methusalem funding. Furthermore, Methusalem funding has been used to buy laptops and powerful desktops as well as to fund participation at scientific conferences of its Methusalem‐funded researchers.

Investments in expert personnel 20082009 CenStat has attracted two predoctoral researchers focusing on both the application and the development of statistical methodology in the collaboration with the research partners at UA. This role is also taken up by a postdoctoral fellow who, additionally, supervises the collaboration between CenStat and Vaxinfectio.

Future Investments In collaboration with one of the Vaxinfectio units, the supervising postdoctoral fellow has been awarded a scientific chair in evidence‐based vaccinology at UA on a part‐time basis and continues to supervise and expand the collaboration between CenStat and Vaxinfectio from a shared UA‐UH position. Next to this, a third predoctoral researcher will be appointed in 2010. Given the available funding, CenStat will continuously recruit new pre‐ and postdoctoral researchers to maximize the implementation of the Methusalem research plan. It will also further expand its computing facilities and active participation at international conferences by presentations and short courses presenting up‐to‐date statistical methodology as used in the research activities of the consortium.

- Budget & Investments -

66


67

10 Annexes

Annex I: Administrative information Annex II: List of papers, book and book chapters Annex III: Programmes of the workshops/conferences Annex IV: Extract from the Flemish Government Directive Annex V: Personnel list

- Annex I -

68


69

10.1 ANNEX I: Administrative Information Team leader at the University of Antwerp: Prof. Dr. Herman Goossens Responsibile for the scientific and technical coordination of the project at the University of Antwerp. Address: Medical Microbiology, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐821.37.87 Fax number: +32‐3‐825.42.81 Email: [email protected] or [email protected] Leading researchers: These are leading the collaborating research units, which constitute the Centre of Excellence, Vaxinfectio. 1. Prof. Dr. Pierre Van Damme Address: CEV, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.25.38 Fax number: +32‐3‐265.26.40 Email: [email protected] 2. Prof. Dr. Zwi Berneman Address: UZA, Wilrijkstraat 10, BE 2650 Edegem Telephone: +32‐3‐821.37.80 Fax number: +32‐3‐821.42.86 Email: [email protected] Team leader at Hasselt University: Prof. Dr. Geert Molenberghs Responsibile for the scientific and technical coordination of the project at Hasselt University. Address: Center for Statistics, Hasselt University, Campus Diepenbeek, Agoralaan 1, BE 3590, Diepenbeek. Telephone: +32‐11‐26.82.38 or +32‐11‐26.82.02 Fax number: +32‐11‐26.82.99 Email: [email protected] Leading researchers: 1. Prof. Dr. Marc Aerts Address: Center for Statistics, Hasselt University, Campus Diepenbeek, Agoralaan 1, BE 3590, Diepenbeek. Telephone: +32‐11‐26.82.47 or +32‐11‐26.82.02 Fax number: +32‐11‐26.82.99 Email: [email protected] 2. Prof. Dr. Ziv Shkedy Address: Center for Statistics, Hasselt University, Campus Diepenbeek, Agoralaan 1, BE 3590, Diepenbeek. Telephone: +32‐11‐26.82.40 or +32‐11‐26.82.02 Faxumber: +32‐11‐26.82.99 Email: [email protected] 3. Prof. Dr. Niel Hens Address: Center for Statistics, Hasselt University, Campus Diepenbeek, Agoralaan 1, BE 3590, Diepenbeek. Telephone: +32‐11‐26.82.32 or +32‐11‐26.82.02 Faxumber: +32‐11‐26.82.99 Email: [email protected]

- Annex I -

70

Research and Innovation Manager (IOF): Responsible for overall management and technology transfer of the Vaxinfectio & Methusalem consortium. Dr. Vanessa Vankerckhoven Address: Medical Microbiology, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.21.57 Fax number: +32‐3‐265.27.52 E‐mail: [email protected] Administrative coordinator: Responsibile for the administrative and financial coordination of the Vaxinfectio & Methusalem consortium. Gino Verwimp Address: Department of Epidemiology and Social Medicine, Campus Drie Eiken, Universiteitsplein 1, BE 2610 Antwerpen Telephone: +32‐3‐265.25.21 Fax number: +32‐3‐265.26.40 Email: [email protected] Recipient institution 1: University of Antwerp Legal address: Contact address: Stadscampus Campus Drie Eiken Prinsstraat 13 Universiteitsplein 1 BE 2000 Antwerpen BE 2610 Antwerpen Recipient institution 2: Hasselt University Legal and contact address: Campus Diepenbeek Agoralaan 1 BE 3590 Diepenbeek Participating institution: Universitair Ziekenhuis Antwerpen (UZA) Legal and contact address: Wilrijkstraat 10 2650 Edegem


71

10.2 ANNEX II: List of Papers, Books and Book chapters 2009 In press

• Creemers A., Hens N., Aerts M., Molenberghs G., Verbeke G., Kenward M. A Sensitivity Analysis for Shared‐parameter Models. ‐ In: The Biometrical Journal. In Press.

• Creemers A., Hens N., Aerts M., Molenberghs G., Verbeke G., Kenward M. Shared‐parameter Models and Missingness at Random". In: Statistical Modelling. In Press.

• Hens N., Kvitkovicova A., Aerts M., Hlubinka D., Beutels P. Modelling Distortion in Seroprevalence Data Using Change‐point Fractional Polynomials. In: Statistical Modelling. In Press.

• Parolini O, Alviano F, Bergwerf I, Boraschi D, De Bari C, De Waele P, Dominici M, Evangelista M, Falk W, Hennerbichler S, Hess DA, Lanzoni G, Liu B, Marongiu F, McGuckin C, Mohr S, Nolli ML, Ofir R, Ponsaerts P, Romagnoli L, Solomon A, Soncini M, Strom S, Surbek D, Venkatachalam S, Wolbank S, Zeisberger S, Zeitlin A, Zisch A, Borlongan CV. Toward cell therapy using placenta‐derived cells: Disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. In: Stem Cells and Development. In press. Joint publications UA‐UH (also listed under Vaxinfectio and CenStat separately)

• Bilcke J., Van Damme P., Van Ranst M., Hens N., Aerts M., Beutels P. Estimating the Incidence of Symptomatic Rotavirus Infections: A Systematic Review and Meta‐Analysis." – In: PLoS ONE:2009:Jun: 26:4(6).

• Hens N., Aerts M., Faes C., Shkedy Z., Lejeune O., Van Damme P., Beutels, P. 75 years of estimating the force of infection" ‐ In: Epidemiology and Infection 21 (2009), p. 1‐11.

• Hens N., Goeyvaerts N., Aerts M., Shkedy Z., Van Damme P., Beutels P. Mining social mixing patterns for infectious disease models based on a two‐day population survey in Belgium. ‐ In: BMC Infectious Diseases, 20:9:5 (2009).

• Hens N., Minalu Ayele G., Goeyvaerts N., Aerts M., Mossong J., Edmunds W., Beutels P. Estimating the Impact of School Closure on Social Mixing Behaviour and the Transmission of Close Contact Infections in Eight European Countries" –In: BMC Infectious Diseases, 931,1‐5,18 (2009).

• Ogunjimi B., Hens N., Goeyvaerts N., Aerts M., Beutels P. Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella. ‐ In: Mathematical Biosciences, 278:2 (2009), p. 80‐87.

• Theeten H., Hens N., Aerts M., Vandermeulen C., Roelants M., Hoppenbrouwers K. and Van Damme P., Beutels P. Caregiver concerns about the number of vaccine injections and willingness to pay to reduce them.‐ In: The Pediatric Infectious Disease Journal. 28:1 (2009), p. 61‐63.

• Theeten H., Hens N., Aerts M., Vandermeulen C., Roelants M., Hoppenbrouwers K., Van Damme P., Beutels P. Common attitudes about concomitant vaccine injections for infants and adolescents in Flanders, Belgium. ‐ In: Vaccine. 27:13 (2009), p. 1964‐1969.

• Van Effelterre T., Shkedy Z., Aerts M., Molenberghs G., Van Damme P., Beutels P. Contact patterns and their implied basic reproductive numbers: an illustration for varicella‐zoster virus.‐ In: Epidemiology and infection, 137:1(2009), p. 48‐57

• Van Heirstraeten L., Cortinas J., Lammens C., Lee A., Harbarth S., Molenberghs G., Aerts M., Goossens H, Malhotra S., on behalf of the MOSAR WP2 Study Group (2009). Impact of a Short Period of Pre‐Enrichment on Detection and Bacterial Loads of Methicillin‐Resistant Staphylococcus aureus from Screening Specimens. ‐In: Journal of Clinical Microbiology, 47:10 (2009), p. 3326‐3328 Vaxinfectio

• Alvarez‐Pasquín M.J., Heijbel H., Yarwood J., Van Damme P. VACSATC (vaccine safety: attitudes, training and communication): why such a project?. ‐ In: Eurosurveillance: European communicable disease bulletin, 14:16(2009), p. 19181,1‐19181,4.

• Anguille S., Smits E., Cools N., Goossens H., Berneman Z., and Van Tendeloo V. Short‐term cultured, interleukin‐15 differentiated dendritic cells have potent immunostimulatory properties. In: Journal of Translational Medicine, 7:1(2009), p. 109.

- Annex II -

72

• Arbyn M., Benoy I., Simoens C., Bogers J., Beutels P., Depuydt C. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. ‐ In: Cancer epidemiology, biomarkers and prevention, 18:1(2009), p. 321‐330.

• Bergwerf I., De Vocht N., Tambuyzer B., Verschueren J., Reekmans K., Daans J., Ibrahimi A., van Tendeloo V., Chatterjee S., Goossens H., Jorens P., Baekelandt V., Ysebaert D., Van Marck E., Berneman Z., Van der Linden AM., Ponsaerts P. Reporter gene‐expressing bone marrow‐derived stromal cells are immune‐tolerated following implantation in the central nervous system of syngeneic immunocompetent mice.‐ In: BMC Biotechnology, (2009), p. 1‐14.

• Beutels P., Scuffham P., MacIntyre C. Funding of drugs: do vaccines warrant a different approach? Authors' reply.‐ In: The lancet infectious diseases, 9:5(2009), p. 270‐271

• Beutels P., Jia N., Zhou Q., Smith R., Cao W., de Vlas S. The economic impact of SARS in Beijing, China.‐ In: Tropical medicine and international health, 14:S:1(2009), p. 85‐91

• Bilcke J., Van Damme P., Van Ranst M., Hens N., Aerts M., Beutels P. Estimating the Incidence of Symptomatic Rotavirus Infections: A Systematic Review and Meta‐Analysis." – In: PLoS ONE:2009:Jun: 26:4(6).

• Bilcke J., Van Damme P., Beutels P. Cost‐effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care" disease impact in Belgium.‐ In: Medical decision making, 29:1(2009), p. 33‐50.

• Bilcke J., Beutels P. Reviewing the cost‐effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources.‐ In: Pharmacoeconomics, 27:4(2009), p. 281‐297.

• Butler C.C., Hood K., Verheij T., Little P., Melbye H., Nuttall J., Kelly M.J., Mölstad S., Godycki‐Cwirko M., Almirall J., Torres A., Gillespie D., Rautakorpi U., Coenen S., Goossens H. Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries.‐ In: British medical journal, 338(2009), p. b2242,1‐b2242 ,8.

• Cavalie, P., Amadeo, B., Goossens, H., and Muller, A. Antibiotic consumption in French hospital system over an 11‐year period (1997‐2007): Results of the ESAC retrospective data collection – In: Antibiotiques 11:4 (2009): 212‐217.

• Ciarlet M., He S., Lai S., Van Damme P., et al. Concomitant use of the 3‐dose oral pentavalent rotavirus vaccine with a 3‐dose primary vaccination course of a diphtheria‐tetanus‐acellular pertussis‐hepatitis B‐inactivated polio‐haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.‐ In: The pediatric infectious disease journal, 28:3(2009), p. 177‐181.

• Claeys K., Züchner S., Kennerson M., Berciano J., Garcia A., Verhoeven K., Storey E., Merory J., Bienfait H., Lammens M., Nelis E., Baets J., de Vriendt E., Berneman Z., De Veuster I., Vance J., Nicholson G., Timmerman V., De Jonghe P. Phenotypic spectrum of dynamin 2 mutations in Charcot‐Marie‐Tooth neuropathy.‐ In: Brain, 132:7(2009), p. 1741‐1752.

• Coenen S., Muller A., Adriaenssens N., Vankerckhoven V., Hendrickx E., Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): outpatient parenteral antibiotic treatment in Europe.‐ In: The journal of antimicrobial chemotherapy, 64:1(2009), p. 200‐205.

• David M., Van Herck K., Hardt K., Tibaldi F., Dubin G., Descamps D., Van Damme P. Long‐term persistence of anti‐HPV‐16 and ‐18 antibodies induced by vaccination with the AS04‐adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.‐ In: Gynecologic oncology, (2009), Dec.,115: S1‐6.

• De Caluwé E., De Smedt S., Assogbadjo A.E., Samson R., Sinsin B., Van Damme P. Ethnic differences in use value and use patterns of baobab (Adansonia digitata L.) in northern Benin.‐ In: African journal of ecology, 47:3(2009), p. 433‐440.

• De Hert M., Franic T., Vidovic D., Wampers M., Van Eyck D., Van Herck K., Van Damme P., Peuskens J. Prevalence of HIV and hepatitis C infection among patients with schizophrenia.‐ In: Schizophrenia research, 108(2009), p. 307‐308.

• Gadisseur A., Hermans C., Berneman Z., Schroyens W., Deckmyn H., Michiels J. Laboratory diagnosis and molecular classification of von Willebrand disease.‐ In: Acta haematologica, 121:2/3(2009), p. 71‐84.

• Gadisseur A., Berneman Z., Schroyens W., Michiels J. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1‐B3 and C1‐C2 domains of the von Willebrand factor gene: role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.‐ In: Acta haematologica, 121:2/3(2009), p. 128‐138.

• Gadisseur A., Van der Planken M., Schroyens W., Berneman Z., Michiels J. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss‐of‐


73

function mutations in the A1 domain of the von Willebrand factor gene.‐ In: Acta haematologica, 121:2/3(2009), p. 145‐153.

• Goossens H.‐ Antibiotic consumption and link to resistance.‐ In: Clinical microbiology and infection, 15:S:3(2009), p. 12‐15.

• Hens N., Aerts M., Faes C., Shkedy Z., Lejeune O., Van Damme P., Beutels, P. 75 years of estimating the force of infection" ‐ In: Epidemiology and Infection, 21 (2009), p. 1‐11.

• Hens N., Goeyvaerts N., Aerts M., Shkedy Z., Van Damme P., Beutels P. Mining social mixing patterns for infectious disease models based on a two‐day population survey in Belgium. ‐ In: BMC Infectious Diseases 20:9:5 (2009).


• Jit M., Bilcke J., Mangen M., Salo H., Melliez H., Edmunds W., Yazdan Y., Beutels P. The cost‐effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe.‐ In: Vaccine, 27:44(2009), p. 6121‐6128.

• Lambrechts N., Verstraelen S., Lodewyckx H., Felicio A., Hooyberghs J., Witters H., Van Tendeloo V., van Cauwenberge P., Nelissen I., van den Heuvel R., Schoeters G.. THP‐1 monocytes but not macrophages as a potential alternative for CD34+ dendritic cells to identify chemical skin sensitizers.‐ In: Toxicology and applied pharmacology, 23:2(2009), p. 221‐230.

• Lion E., Smits E., Berneman Z., Van Tendeloo V. Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN‐ secretion by human NK cells .‐ In: Leukemia research, 33:4(2009), p. 539‐546.

• Lion E. , Smits E. , Berneman Z., van Tendeloo V. Quantification of IFN−produced by human purified NK cells following tumor cell stimulation: comparison of three IFN−assays.‐ In: Journal of immunological methods, 350(2009), p. 89‐96.

• Loens K., Van Heirstraeten L., Malhotra S., Goossens H., Ieven M. Optimal sampling sites and methods for detection of pathogens possibly causing community‐acquired lower respiratory tract infections.‐ In: Journal of clinical microbiology, 47:1(2009), p. 21‐31.

• Luyten J., Beutels P. Costing infectious disease outbreaks for economic evaluation: a review for hepatitis A.‐ In: Pharmacoeconomics, 27:5(2009), p. 379‐389.

• Malhotra S., Coenen S. , Klugman K., Goossens H. 3‐monthly azithromycin administration for trachoma.‐ In: The lancet: international edition, 374:9688(2009), p. 449.

• Malhotra S., Van Heirstraeten L., Lammens C., Chapelle S., Goossens H. Emergence of high‐level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.‐ In: The journal of antimicrobial chemotherapy, 63:5(2009), p. 886‐894.

• Malhotra S., Mazzariol A., van Heirstraeten L., Lammens C., De Rijk P., Cornaglia G., Goossens H. Unusual resistance patterns in macrolide‐resistant Streptococcus pyogenes harbouring erm(A).‐ In: The journal of antimicrobial chemotherapy, 63:1(2009), p. 42‐46.

• Mebis J., Vandeplassche S., Goossens H., Berneman Z. Cefepime and amikacin as empirical therapy in patients with febrile neutropenia: a single‐centre phase II prospective survey.‐ In: Acta clinica Belgica, 64:1 (2009), p. 35‐41.

• Michiels J., Berneman Z., Gadiseur A., van der Planken M., Schroyens W., van Vliet H. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.‐ In: Acta haematologica, 121:2/3(2009), p. 85‐97

• Michiels J., Van Vliet H., Berneman Z., Schroyens W., Gadisseur A. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor‐factor VIII concentrate in surgical settings.‐ In: Acta haematologica, 121:2/3(2009), p. 167‐176.

• Michiels J., Gadisseur A., Vangenegten I., Schroyens W., Berneman Z. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.‐ In: Acta haematologica, 121:2/3(2009), p. 119‐127.

• Michiels J., Gadisseur A., van der Planken M., Schroyens W., Berneman Z. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains. ‐ In: Acta Haematol., 121:2‐3 (2009), p. 111‐8. Epub 2009 Jun 8.

• Nardone A., Anastassopoulou C.G., Theeten H., Van Damme P., et al. A comparison of hepatitis B seroepidemiology in ten European countries.‐ In: Epidemiology and infection, 137:7(2009), p. 961‐969.

- Annex II -

74

• Noens L., Van Lierde M., De Bock R., Verhoef G., Zachée P., Berneman Z., Martiat P., Mineur P., Van Eygen K., MacDonald K., De Geest S., Albrecht T., Abraham I. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. ‐ In: Blood, 113:22 (2009), p. 5401‐11. Epub 2009 Apr 6.

• Ogunjimi B., Hens N., Goeyvaerts N., Aerts M., Beutels P. Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella. ‐ In: Mathematical Biosciences, 278:2 (2009), p. 80‐87.

• Raschi E., Poluzzi E., Zuliani C., Muller A., Goossens H., De Ponti F. Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8‐year period. ‐In: Clin Pharmacol, 67 (2009), p. 88‐98.

• Smits E., Berneman Z., Van Tendeloo V. Immunotherapy of acute myeloid leukemia: current approaches.‐ In: The oncologist, 14:3(2009), p. 240‐252.

• Smits E., Anguille S., Cools N., Berneman Z., Van Tendeloo V. Dendritic cell‐based cancer gene therapy.‐ In: Human gene therapy, 20:10(2009), p. 1106‐1118.

• Tambuyzer B., Bergwerf I., de Vocht N., Reekmans K., Daans J., Jorens P., Goossens H., Ysebaert D., Chatterjee S., Van Marck E., Berneman Z., Ponsaerts P. Allogeneic stromal cell implantation in brain tissue leads to robust microglial activation.‐ In: Immunology and cell biology, 87(2009), p. 267‐273.

• Theeten H., Hens N., Aerts M., Vandermeulen C., Roelants M., Hoppenbrouwers K. and Van Damme P., Beutels P. Caregiver concerns about the number of vaccine injections and willingness to pay to reduce them.‐ In: The Pediatric Infectious Disease Journal. 28:1(2009), p. 61‐63.

• Theeten H., Hens N., Aerts M., Vandermeulen C., Roelants M., Hoppenbrouwers K., Van Damme P., Beutels P. Common attitudes about concomitant vaccine injections for infants and adolescents in Flanders, Belgium. ‐ In: Vaccine, 27:13(2009), p. 1964‐1969.

• Theeten H., Vandermeulen C., Roelants M., Hoppenbrouwers K., Depoorter A., Van Damme P. Coverage of recommended vaccines in children at 78 years of age in Flanders, Belgium.‐ In: Acta paediatrica, 98:8(2009), p. 1307‐1312.

• Vandermeulen C., Clement F., Roelants M., Van Damme P., Hoppenbrouwers K., Leroux‐Roels G. Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination.‐ In: The journal of infectious diseases, 199:10(2009), p. 1457‐1460.

• Van Damme P., Van Sonnenburg F., Hatz C., Hoet B., Lefevre I., Leyssen M. Long‐term immunogenicity of preservative‐free hepatitis B vaccine formulations in adults.‐ In: Journal of medical virology, 81:10(2009), p. 1710‐1715.

• Van Damme P., Oosterhuis‐Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.‐ In: Vaccine, 27:3(2009), p. 454‐459.

• Van Damme P., Minervini G., Liss C., McCarson B., Vesikari T., Boslego J., Bhuyan P. Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults.‐ In: Human vaccines, 5:2(2009), p. 92‐97.

• Van Driessche A., Van de Velde A., Nijs G., Braeckman T., Stein B., de Vries J., Berneman Z., Van Tendeloo V. Clinical‐grade manufacturing of autologous mature mRNA‐electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose‐escalation clinical trial.‐ In: Cytotherapy, 11:5(2009), p. 653‐668.

• Van Effelterre T., Shkedy Z., Aerts M., Molenberghs G., Van Damme P., Beutels P. Contact patterns and their implied basic reproductive numbers: an illustration for varicella‐zoster virus.‐ In: Epidemiology and infection, 137:1(2009), p. 48‐57.

• Van Heirstraeten L., Cortinas J., Lammens C., Lee A., Harbarth S., Molenberghs G., Aerts M., Goossens H, Malhotra S., on behalf of the MOSAR WP2 Study Group (2009). Impact of a Short Period of Pre‐Enrichment on Detection and Bacterial Loads of Methicillin‐Resistant Staphylococcus aureus from Screening Specimens. ‐In: Journal of Clinical Microbiology, 47:10(2009), p. 3326‐3328.

• Vorsters A., Van Herck K., Van Damme P. The clock is running.‐ In: Vaccine, 27:22(2009), p. 2905‐2906. CenStat

• Bilcke J., Van Damme P., Van Ranst M., Hens N., Aerts M., Beutels P. Estimating the Incidence of Symptomatic Rotavirus Infections: A Systematic Review and Meta‐Analysis." PLoS ONE:2009:Jun: 26:4(6).


75

• Boulet G., Benoy I., Depuydt E., HorvathC., Aerts M., Hens N., Vereecken A., Bogers J. HPV16 load and integration as biomarkers for CIN2+ lesions in HPV16‐positive women. ‐ In: Cancer Epidemiology, Biomarkers & Prevention, 18:11(2009), p. 2992‐9.

• Hens N., Aerts M., Faes C., Shkedy Z., Lejeune O., Van Damme P., Beutels, P. 75 years of estimating the force of infection" ‐ In: Epidemiology and Infection, 21(2009), p. 1‐11.

• Hens N., Goeyvaerts N., Aerts M., Shkedy Z., Van Damme P., Beutels P. Mining social mixing patterns for infectious disease models based on a two‐day population survey in Belgium. ‐ In: BMC Infectious Diseases, 20:9:5 (2009).


• Hens N., Wienke A., Aerts M., Molenberghs G. The Correlated and Shared Gamma Frailty Model for Bivariate Current Status Data: An Illustration for Cross‐sectional Serological Data." ‐ In: Statistics in Medicine, 28:22 (2009), p. 2785‐800.

• Mossong J., Hens N. et al. Epidemiology of parvovirus B19 infection in Europe: results from a seroprevalence studies in Belgium, England and Wales, Finland, Italy and Poland. ‐ In: Epidemiology and Infection, 136:8(2009), p. 1059‐1068.

• Ogunjimi B., Hens N., Goeyvaerts N., Aerts M., Beutels P. Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella. ‐ In: Mathematical Biosciences, 278:2(2009), p. 80‐87.

• Theeten H., Hens N., Aerts M., Vandermeulen C., Roelants M., Hoppenbrouwers K. and Van Damme P., Beutels P. Caregiver concerns about the number of vaccine injections and willingness to pay to reduce them.‐ In: The Pediatric Infectious Disease Journal, 28:1(2009), p. 61‐63.

• Theeten H., Hens N., Aerts M., Vandermeulen C., Roelants M., Hoppenbrouwers K., Van Damme P., Beutels P. Common attitudes about concomitant vaccine injections for infants and adolescents in Flanders, Belgium. ‐ In: Vaccine, 27:13(2009), p. 1964‐1969.

• Van Effelterre T., Shkedy Z., Aerts M., Molenberghs G., Van Damme P., Beutels P. Contact patterns and their implied basic reproductive numbers: an illustration for varicella‐zoster virus.‐ In: Epidemiology and infection, 137:1(2009), p. 48‐57.

• Van Heirstraeten L., Cortinas J., Lammens C., Lee A., Harbarth S., Molenberghs G., Aerts M., Goossens H, Malhotra S., on behalf of the MOSAR WP2 Study Group (2009). Impact of a Short Period of Pre‐Enrichment on Detection and Bacterial Loads of Methicillin‐Resistant Staphylococcus aureus from Screening Specimens. ‐In: Journal of Clinical Microbiology, 47:10(2009), p. 3326‐3328. Books & Book Chapters

• Bilcke J., van Damme P., Beutels P. The burden of rotavirus acute gastroenteritis in Europe.‐ In: Handbook of disease burdens and quality of life measures / Preedy, V.R. [edit.]; et al. [edit.], Berlin, Springer, 2009, p. 1‐10.‐ In press

• Cools N., Van Tendeloo V., Berneman Z.‐ Dendritic cells.‐ In: Encyclopedia of cancer, 2 ed., Heidelberg, Springer, 2009

• Loens K., Goossens H., and Ieven M. Update on the detection and characterization of bacterial pathogens by nucleic acid amplification. In: David Persing, Editor in Chief. Molecular Microbiology: Diagnostic principles and practice. In press.

• Ieven M. Microbiological diagnosis of respiratory tract infections in the immunocompromised. In: Carlos Agusti and Antoni Torres, Editors. Pulmonary infection in the immunocompromised patient. 2009, pg 29‐45.

• Walker D., Beutels P., Hutubessy R. Economic evaluation of childhood vaccines.‐ In: Economic evaluation in child health / Ungar, W. [edit.], S.l., 2009, p. 1‐27. 2008 Joint publications UA‐UH (also listed under Vaxinfectio and CenStat separately)

• Hens N., Aerts M., Shkedy Z., Kimani P., Kojouharova M., Van Damme P., Beutels, P. Modeling Age‐time Dependent Incidence Rates of Hepatitis B and Estimating the Prevalence and Force of Infection using Generalized Additive Models." ‐ In: Epidemiology and Infection, 2008:Volume 136, Issue 03, pp 341‐351.

- Annex II -

76

• Hens N., Aerts M., Shkedy Z., Theeten H., Van Damme P., Beutels P. Modelling multi‐sera data: The estimation of new joint and conditional epidemiological parameters." ‐In: Statistics in Medicine, 2008:27, 2651‐2664.

• Mossong J., Hens N., Jit M., Beutels P., Auranen K., Mikolajczyk R. Massari M., Scalia Tomba G., Wallinga J., Sadkowska‐Todys R., Edmunds J. Social contacts and mixing patterns relevant to the spread of infectious diseases. ‐ In: PLoS Med:2008:Mar25: 5(3) e74.

• Mossong J., Hens N., Friederichs V., Davidkin I., Broman M., Litwinska B., Siennicka J., Trzcinska A., Van Damme P., Beutels P., Vyse A., Shkedy Z., Aerts M., Massari M., Gabutti G. Parvovirus b19 infection in five European countries: seroepidemiology, forceand infection and maternal risk of infection. ‐ In: Epidemiology and infection 2008: Aug: 136(8):1059‐68. Vaxinfectio

• Beutels P., Edmunds W.J., Smith R.D. Partially wrong? Partial equilibrium and the economic analysis of public health emergencies of international concern. ‐In: Health Econ. (2008) 17: 1317–1322.

• Beutels P., Scuffham P., MacIntyre C.‐ Funding of drugs: do vaccines warrant a different approach?. In: The lancet infectious diseases, 8:11(2008), p. 727‐733.

• Bilcke J., Van Damme P., Beutels P. Cost‐Effectiveness of Rotavirus Vaccination: Exploring Caregiver(s) and ‘‘No Medical Care’’ Disease Impact in Belgium; ‐In: Med Decis Making OnlineFirst, published on October 23, 2008 as doi:10.1177/0272989X08324955.

• Bilcke J., Van Damme P., De Smet F., Hanquet G., Van Ranst L., Beutels P. The health and economic burden of rotavirus disease in Belgium ‐ In: Eur J Pediatr (2008) 167:1409–1419.

• Borg M., Zarb P., Ferech M., Goossens H. Antibiotic consumption in southern and eastern Mediterranean hospitals: results from the ARMed project. ‐ In: The journal of antimicrobial chemotherapy, 62:4(2008), p. 830‐836.‐ On behalf of the ARMed Project Group.

• Brabin L., Greenberg D., Hessel., Hyer R., Ivanoff B., van Damme P. Current issues in adolescent immunization.‐ In: Vaccine, 26:33(2008), p. 4120‐4133.

• Coenen S., Costers M., De Corte S., De Sutter A., Goossens H. The first European Antibiotic Awareness Day after a decade of improving outpatient antibiotic use in Belgium. ‐ In: Acta Clin Belg 2008:63:296‐300.

• Coenen S., Costers M., De Corte S., De Sutter A., Goossens H. Feed Back sur les « campagnes antibiotiques » belges. ‐In: La Revue de la Médecine Générale 2008;(257):286‐9.

• Coenen S., Costers M., De Corte S., De Sutter A., Goossens H. De eerste Europese Antibioticadag. ‐ In: Huisarts Nu 2008; 37: 446‐450.

• Coenen S., Ferech M.,Haaijer‐Ruskamp F.M., Butler C.C., Vander Stichele R.H., Verheij T.J.M., Monnet D.L., Little P., Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): kwaliteitsindicatoren voor het antibioticagebruik in de ambulante praktijk.‐ In: Huisarts nu: maandblad van de Wetenschappelijke Vereniging van Vlaamse Huisartsen, 37(2008), p. 456‐462

• Cools N., van Tendeloo V., Smits E., Lenjou M., Nijs G., Van Bockstaele D., Berneman Z., Ponsaerts P. Immunosuppression induced by immature dendritic cells is mediated by TGF‐beta/IL‐10 double‐positive CD4+ regulatory T cells.‐ In: Journal of cellular and molecular medicine, 12:2(2008), p. 690‐700

• Davey P., Ferech M., Ansari F., Muller A., Goossens H.; on behalf of the ESAC Project Group. Outpatient Antibiotic use in the four administrations of the UK: cross‐sectional and longitudinal analysis. ‐ In: Antimicrob Chemother 2008,Dec:62(6):1441‐7.

• De Sutter A., Coenen S. De Europese Antibioticadag van 18 November 2008. ‐In: Folia Pharmacotherapeutica 2008; 35: 96.

• Duesberg C., Malhotra S., Goossens H., McGee L., Klugman K., Welte T., Pletz M. Interspecies recombination occurs frequently in quinolone resistance‐determining regions of clinical isolates of Streptococcus pyogenes.‐ In: Antimicrobial agents and chemotherapy, 52:11(2008), p. 4191‐4193

• FitzSimons D., François G., De Carli G., Shouval D., Prüss‐Üstün A., Puro V., Williams I., Lavanchy D., De Schryver A., Kopka A., Ncube F., Ippolito G., Van Damme P. Hepatitis B virus, hepatitis C virus and other blood‐borne infections in healthcare workers: guidelines for prevention and management in industrialised countries. ‐In: Occup Environ Med 2008: 1‐8.

• Goossens H., Coenen S., Costers M., De Corte S., De Sutter A., Gordts B., Laurier L., Struelens M. The Belgian Antibiotic Policy Coordination Committee (BAPCOC). ‐ In: Eurosurveillance 2008; 13: 10‐13.

• Gray J., Vesikari T., Van Damme P., Giaquinto C., Mrukowicz J., Guarino A., Dagan R., Szajewska H., Usonis V. Rotavirus. ‐In: Pediatr Gastroenterol Nutr 2008; 46: 1‐8.


77

• Hendrickx G., van Herck K., Vorsters A., Wiersma S., Shapiro C., Andrus J.K., Ropero A.M., Shouval D., Ward W., van Damme P. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology.‐ In: Journal of viral hepatitis, 15:S:2(2008), p. 1‐15

• Hens N., Aerts M., Shkedy Z., Theeten H., van Damme P., Beutels P.‐Modelling multisera data: the estimation of new joint and conditional epidemiological parameters.‐ In: Statistics in medicine, 27:14(2008), p. 2651‐2664

• Hens N., Aerts M., Shkedy Z., Kimani P.K., Kojouharova M., Van Damme P., Beutels P. Estimating the impact of vaccination using age‐time‐dependent incidence rates of hepatitis B.‐ In: Epidemiology and infection, 136:3(2008), p. 341‐351

• Koulova A., Tsui J., Irween K., Van Damme P., Biellik R., Aguado MT. A brief report: Country recommendations on the inclusion of HPV vaccnes in national immunization programmes among high‐income countries. June 2006 – January 2008. ‐ In: Vaccine 2008; Dec: 2:26(51):6529‐41.

• Loens K., Beck T., Ursi D., Overdijk M., Sillekens P., Goossens H., Ieven M. Development of real‐time multiplex nucleic acid sequence‐based amplification for detection of Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella spp. in respiratory specimens.‐ In: Journal of clinical microbiology, 46:1(2008), p. 185‐191

• Loens K., Beck T., Ursi D., Overdijk M., Sillekens P., Goossens H., Ieven M. Evaluation of different nucleic acid amplification techniques for the detection of M. pneumoniae, C. pneumoniae and Legionella spp. in respiratory specimens from patients with community‐acquired pneumonia.‐ In: Journal of microbiological methods, 73(2008), p. 257‐262

• Loens K., Ursi D., Goossens H., Ieven M. Evaluation of the NucliSens miniMAG RNA extraction and real‐time NASBA applications for the detection of Mycoplasma pneumoniae and Chlamydophila pneumoniae in throat swabs.‐ In: Journal of microbiological methods, 72:2(2008), p. 217‐219

• Malhotra S., Haccuria K., Michiels M., Ieven M., Poyart C., Hryniewicz W., Goossens H. Current trends in rapid diagnostics for methicillin‐resistant Staphylococcus aureus and glycopeptide‐resistant Enterococcus species.‐ In: Journal of clinical microbiology, 46:5(2008), p. 1577‐1587

• Marcel J.‐P., Alfa M., Baquero F., Etienne J., Goossens H., Harbarth S., Hryniewicz W., Jarvis W., Kaku M., Leclercq R., Levy S., Mazel D., Nercelles P., Perl T., Pittet D., Vandenbroucke‐Grauls C., Woodford N., Jarlier V.. Healthcare‐associated infections: think globally, act locally.‐ In: Clinical microbiology and infection, 14:10(2008), p. 895‐907

• Matheï C., Van Dooren S., Lemey P., Van Damme P., Buntinx F., Vandamme AM. The epidemic history of hepatitis C among injecting drug users in Flanders, Belgium. ‐ In: Viral Hepat. 2008 Jan:15(6):399‐408.

• Michielsen P., Van Herck K., Van Damme P. NHG‐Standaard virushepatitis en andere leveraandoeningen. Toepasbaar voor België? ‐ In: Huisarts Nu 2008; 37: 372‐378.

• Mossong J., Hens N., Friederichs V., Davidkin I., Broman M., Litwinska B., Siennicka J., Trzcinska A., Van Damme P., Beutels P., Vyse A., Shkedy Z., Aerts M., Massari M., Gabutti G. Parvovirus b19 infection in five European countries: seroepidemiology, forceand infection and maternal risk of infection. ‐ In: Epidemiology and infection 2008: Aug: 136(8):1059‐68.

• Mossong J., Hens N., Jit M., Beutels P., Auranen K., Mikolajczyk R., Massari M., Salmaso S., Scalia Tomba G., Wallinga J., Heijne J., Sadkowsk‐Todys M., Rosinska M., Edmunds W. Social contacts and mixing patterns relevant to the spread of infectious diseases.‐ In: PLoS medicine, 5:3(2008), p. e74,1‐13

• O’hara S, Malhotra S, Haccuria K, Van Heirstraeten L, Ieven M, Goossens H. Novel rapid culture‐based detection method for methicillin‐resistant Staphylococcus aureus. – In: Journal of Clinical Microbiology 2008 Sep;46(9):3181

• Richter S., Heilmann K., Dohrn C., Beekmann S., Riahi F., Garcia‐de‐Lomas J., Ferech M., Goossens H.,Doern G. Increasing telithromycin resistance among Streptococcus pyogenes in Europe.‐ In: The journal of antimicrobial chemotherapy, 61:3(2008), p. 603‐611

• Ronsyn M., Berneman Z., van Tendeloo V., Jorens P., Ponsaerts P. Can cell therapy heal a spinal cord injury?.‐ In: Spinal cord, 46:8(2008), p. 532‐539

• Sengupta N., Booy R., Schmitt H., Peltola H., Van Damme P., Schumacher R., Campins M., Rodrigo C., Heikkinen T., Seward J., Jumaan A., Finn A., Olcén P, Thiry N., Weil‐Olivier C., Breuer J. Varicella vaccination in Europe: are we ready for a universal childhood programme? ‐ In: Eur J Pediatr 2008; 167: 47‐55

- Annex II -

78

• Sleegers K., Brouwers N., Maurer‐Stroh S., van Es M.A., van Damme P., van Vught P.W.J., van der Zee J., Serneels S., de Pooter T., Van den Broeck M., Cruts M., Schymkowitz J., De Jonghe P., Rousseau F., van den Berg L.H., Robberecht W., Van Broeckhoven C. Progranulin genetic variability contributes to amyotrophic lateral sclerosis.‐ In: Neurology, 71:4(2008), p. 253‐259

• Smits E., Ponsaerts P., Berneman Z., Van Tendeloo V. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. ‐ In: The oncologist, 13:8(2008), p. 859‐875

• Theeten H., Van Damme P. Vaccinaties: Eén voor allen, allen voor één? ‐In: Caleidoscoop, jaargang 20 nr 2 – maart‐april 2008, 30‐35.

• Vael C., Nelen V., Verhulst S., Goossens H., Desager K. Early intestinal Bacteroides fragilis colonisation and development of asthma .‐ In: BMC pulmonary medicine, 8:19(2008),

• Van Bockastaele F., Pede V., van Coppernolle S., Van Tendeloo V., Verhasselt B., Philippé J. Efficient gene transfer in CLL by mRNA electroporation.‐ In: Leukemia, 22:2(2008), p. 323‐329

• Van Craenenbroeck E., Vrints C., Haine S., Vermeulen K., Goovaerts I., van Tendeloo V., Hoymans V., Conraads V.‐ Maximal exercise bout increases the number of circulating CD34+/KDR+ endothelial progenitor cells in healthy subjects: relation with lipid profile.‐ In: Journal of applied physiology, 104:4(2008), p. 1006‐1013

• Van Craenenbroeck E., Conraads V., Van Bockstaele D., Haine S., Vermeulen K., Van Tendeloo V., Vrints C., Hoymans V. Quantification of circulating endothelial progenitor cells: a methodological comparison of six flow cytometric approaches.‐ In: Journal of immunological methods, 332:1‐2(2008), p. 31‐40

• Van Damme P., Pecorelli S., Joura E. The introduction of policies for human papillomavirus vaccination in Europe. ‐In: Public Health 16:4(2008), p. 291‐298

• Van Damme P., Oosterhuis‐Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. ‐In: Vaccine, 2008; Jan14:27(3): 454‐9.

• Van de Velde A., Berneman Z., Van Tendeloo V. Immunotherapy of hematological malignancies using dendritic cells.‐ In: Bulletin du cancer, 95:3(2008), p. 320‐326

• Vandermeulen C., Roelants M., Theeten H., Depoorter A., Van Damme P., Hoppenbrouwers K. Vaccination Coverage in 14‐Year‐Old Adolescents: Documentation, Timelines, and Sociodemographic Determinants. ‐In: Pediatrics 2008, 121: 3: 1‐7.

• Vandermeulen C., Roelants M., Theeten H., Van Damme P., Hoppenbrouwers K. Vaccination coverage and sociodemographic determinants of measles‐mumps‐rubella vaccination in three different age groups. ‐In: Eur J Pediatr 2008: Oct:167(10): 1161‐8.

• Van der Wielen M., Van Damme P. Pentavalent human‐bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial. ‐In: Eur J Clin Microbiol Infect Dis 2008; 27: 495‐501.

• Van de Sande‐Bruinsma N., Grundmann H., Verloo D., Tiemersma E., Monen J., Goossens H., Ferech M. Antimicrobial drug use and resistance in Europe.‐ In: Emerging infectious diseases, 14:11(2008), p. 1722‐1730

• Van Gulck Ellen R., Vanham G., Heyndrickx L., Coppens S., Vereecken K., Atkinson D., Florence E., Kint I., Berneman Z., van Tendeloo V. Efficient in vitro expansion of human immunodeficiency virus (HIV)‐specific T‐cell responses by gag mRNA‐electroporated dendritic cells from treated and untreated HIV type 1‐infected individuals.‐ In: Journal of virology, 82:7(2008), p. 3561‐3573

• Van Herck K., Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. ‐In: Ped Infect Dis J 2008; 27: 1‐9.

• Vankerckhoven V., Geert H., Marc V., Cindy S., Jean S., Ingo K., Wolfgang W., Van Autgaerden T., Chapelle S., Lammens C., Goossens H. Genotypic Diversity, Antimicrobial Resistance and Virulence Factors of Human Isolates and Probiotic CulturesConstituting Two Intraspecific Groups in Human and Probiotic Enterococcus faecium Strains. Appl. Environ. ‐ In: Microbiol. 2008; 74(14): 4247‐4255.

• Vankerckhoven V., Huys G., Vancanneyt M., Vael C., Klare I., Romond M., Entenza J., Moreillon P., Wind R., Knol J., Wiertz E., Pot B., Vaughan E., Kahlmeter G., Goossens H. Biosafety assessment of probiotics used for human consumption: recommendations from the EU‐PROSAFE project.‐ In: Trends in food science and technology, 19:2(2008), p. 102‐114

• Van Vré E., Bult H., Hoymans V., Van Tendeloo V., Vrints C., Bosmans J. Human C‐reactive protein activates monocyte‐derived dendritic cells and induces dendritic cell‐mediated T‐cell activation.‐ In: Arteriosclerosis, thrombosis, and vascular biology, 28:3(2008), p. 511‐518


79

• Verhulst S., Vael C., Beunckens C., Nelen V., Goossens H., Desager K. A longitudinal analysis on the association between antibiotic use, intestinal microflora, and wheezing during the first year of life .‐ In: Journal of asthma, 45:9(2008), p. 828‐832

• Vesikari T., Van Damme P., Giaquinto C., Gray J., Mrukowicz J., Dagan R., Guarino A., Szajewska H., Usonis V. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Evidence‐basedRecommendations for Rotavirus Vaccination in Europe. ‐In: Pediatr Gastroenterol Nutr 2008; 45: 18‐28.

• Worth L.J., Slavin M.A., Vankerckhoven V., Goossens H., Grabsch E., Thursky A. Virulence determinants in vancomycin‐resistant Enterococcus faecium vanB: clonal distribution, prevalence and significance of esp and hyl in Australian patients with haematological disorders.‐ In: The journal of hospital infection, 68:2(2008), p. 137‐144

• Zanetti A., Van Damme P., Shouval D. The global impact of vaccination against hepatitis B: a historial overview. ‐In:Vaccine 2008; 26: 6266‐6273. CenStat

• Hens N., Aerts M., Shkedy Z., Kimani P., Kojouharova M., Van Damme P., Beutels, P. Modeling Age‐time Dependent Incidence Rates of Hepatitis B and Estimating the Prevalence and Force of Infection using Generalized Additive Models." ‐ In: Epidemiology and Infection, 2008:Volume 136, Issue 03, pp 341‐351.

• Hens N., Aerts M., Shkedy Z., Theeten H., Van Damme P., Beutels P. Modelling multi‐sera data: The estimation of new joint and conditional epidemiological parameters." ‐In: Statistics in Medicine, 2008:27, 2651‐2664.

• Mossong J., Hens N., Friederichs V., Davidkin I., Broman M., Litwinska B., Siennicka J., Trzcinska A., Van Damme P., Beutels P., Vyse A., Shkedy Z., Aerts M., Massari M., Gabutti G. Parvovirus b19 infection in five European countries: seroepidemiology, forceand infection and maternal risk of infection. ‐ In: Epidemiology and infection 2008: Aug: 136(8):1059‐68.

• Mossong J., Hens N., Jit M., Beutels P., Auranen K., Mikolajczyk R. Massari M., Scalia Tomba G., Wallinga J., Sadkowska‐Todys R., Edmunds J. Social contacts and mixing patterns relevant to the spread of infectious diseases. ‐ In: PLoS Med:2008:Mar25: 5(3) e74.

Books & Book Chapters • Ieven M. Microbiological diagnosis of Community‐Acquired Pneumonia. In: Antoni Torres and Rosario

Menendez, Editors. Community‐Acquired Pneumonia: Stratgies for Management. 2008, pg 43‐62. • Van Herck K., Vorsters A., Van Damme P. Prevention of viral hepatitis (B and C) reassessed.‐ In: Best

practice and research: clinical gastroenterology, 22:6(2008), p. 1009‐1029

- Annex II -

80


81

10.3 ANNEX III: Programmes of the Methusalem Research Days

Methusalem Research Day n°1 (2008)

First Joint Scientific Meeting ‐ Methusalem Consortium:

Vaccine and Infectious Disease Institute (Vaxinfectio),

University of Antwerp

Center for Statistics (CenStat),

University of Hasselt,

September 4, 2008

Background:

The Methusalem Consortium consists of the Vaccine and Infectious Disease Institute (Vaxinfectio) of the

University of Antwerp (UA) and the Center for Statistics (CenStat) of the University of Hasselt (UH). Vaxinfectio

consists of the Laboratory of Medical Microbiology (LMM), the Laboratory of Experimental Hematology (LEH),

and Centre for Evaluation of Vaccination (CEV).

The two research institutes, Vaxinfectio and CenStat, have been awarded Methusalem funding in 2008 and will

organise joint annual scientific meetings.

The first meeting will be organised on September 4, 2008, at the University of Antwerp.

Venue:

Promotiezaal, Campus Drie Eiken (CDE)

Universiteit Antwerpen

Universiteitsplein 1, 2610 Antwerpen

Programme:

9.30 – 10.15: Session 1 – Introduction

Chairs: Greet Ieven, UA – Marc Aerts, UH

9.30 – 9.40: Welcoming

Jean‐Pierre Timmermans, Chairman‐Elect of the Research Council UA

9.40 – 9.45: Objectives of the meeting

Herman Goossens, UA and Geert Molenberghs, UH

9.45 – 10.15: Presentation of Methusalem Research programme

UA research programme:

Herman Goossens, Head of the Laboratory of Medical Microbiology (LMM),

Pierre Van Damme, Head of the Centre for Evaluation of Vaccination (CEV).

Zwi Berneman, Head of the Laboratory of Experimental Hematology (LEH),

Joint UA – UH research programme:

Geert Molenberghs, Director I‐Biostat, UH

10.15 – 12.00 Session 2 – Examples of successful collaborations between the UA and UH

- Annex III -

82

Chairs: Greet Ieven, UA – Marc Aerts, UH

10.15 – 10.45: New statistical tools to evaluate diagnostic tests in medical microbiology: evaluation of

chromogenic media for the detection of nosocomial superbugs

José Cortinas, UH & Surbhi Malhotra, UA

10.45 – 11.00: Discussion

11.00 – 11.45 10 years of collaboration on estimating infectious disease parameters for simulation models

Philippe Beutels, UA & Marc Aerts and Niel Hens, UH


12.00 – 12.30 Lunch

12.30 – 14.00 Session 3 – Time trend and longitudinal data

Chairs: Viggo Van Tendeloo, UA – Niel Hens, UH

12.30 – 13.00: Modeling the long‐term antibody persistence in hepatitis A vaccine recipients

Koen Van Herck, UA & Ziv Shkedy UH


13.15 – 13.45: European surveillance of antimicrobial consumption, outpatient antibiotic use in Europe, and

the effect of public campaigns

Samuel Coenen, UA


14.00 14.45 Session 4 – Clinical trials

Chairs: Viggo Van Tendeloo, UA – Niel Hens, UH

14.00 – 14.30: Statistical models for randomized controlled trials

Geert Molenberghs, UH


14.45 – 15.15 Coffee break

15.15 – 17.00 Session 4 – Continuation

15.15 – 15.45: Measuring the effect of antibiotic use on resistance in randomized controlled trials

Surbhi Malhotra, UA


16.00 – 16.45: Therapeutic vaccines for cancer and infectious diseases using RNA‐modified dendritic cells

Viggo Van Tendeloo


17.00 Closing remarks

Geert Molenberghs, UH

17.30 Reception and buffet


83

Methusalem Research Day n°2 (2009)

Second Joint Scientific Meeting – Methusalem Consortium: Vaccine & Infectious Disease Institute (Vaxinfectio),

University of Antwerp Center for Statistics (CenStat),

University of Hasselt

October 22, 2009

Background: The Methusalem Consortium consists of the Vaccine and Infectious Disease Institute (Vaxinfectio) of the University of Antwerp (UA) and the Center for Statistics (CenStat) of the University of Hasselt (UH). Vaxinfectio consists of the Laboratory of Medical Microbiology (LMM), the Laboratory of Experimental Hematology (LEH), and Centre for Evaluation of Vaccination (CEV). The two research institutes, Vaxinfectio and CenStat, have been awarded Methusalem funding in 2008 and will organise joint annual scientific meetings.

The second meeting will be organised on October 22, 2009, at the University of Antwerp.

Venue: Hof Van Liere Universiteit Antwerpen Prinsstraat 13, 2000 Antwerpen

Programme:

9.30 ‐ 10.15 Session 1 – Introduction

Chair: Geert Molenberghs & Herman Goossens

9.30 – 9.40 Welcome

Bart Nelissen, Research Manager Biomedical Sciences, UA

9.40 – 9.50 Objectives of the meeting

Herman Goossens, UA & Geert Molenberghs, UHasselt

9.50 – 10.15 Translation research in Infectious Diseases

Philippe Jorens, UZA

10.15 – 12.00 Session 2 – Influenza H1N1 and Vaccination

Chair: Pierre Van Damme & Marc Aerts

10.15 – 10.30 State of the art on the H1N1 Epidemic

Pierre Van Damme, UA

10.30 – 11.00 Modelling of H1N1 influenza infection based on confirmed cases

Philippe Beutels, UA & Niel Hens, UHasselt

11.00 – 11.30 Vaccination coverage in infants, Flanders 2008

Heidi Theeten, UA & Niel Hens, UHasselt

11.30 – 12.00 Duration of protection through maternal antibodies

Elke Leuridan, UA & Niel Hens, UHasselt

12.00 – 13.00 Lunch

13.00 – 14.15 Session 4 – Linear Mixed Models

- Annex III -

84

Chair: Geert Molenberghs & Herman Goossens

13.00 – 13.15 State of the art on statistical methods

Geert Molenberghs, UHasselt

13.15 – 13.45 Research on probiotics

Vanessa Vankerckhoven, UA & Marc Aerts, UHasselt

13.45 – 14.15 Research on antibiotics

Samuel Coenen, UA & Christel Faes, UHasselt

14.15 – 15.30 Session 3 – Diagnosis of infections

Chair: Herman Goossens & Niel Hens

14.15 – 14.30 State of the art on point of care diagnositics

Herman Goossens, UA

14.30 – 15.00 Rapid detection of important hospital‐acquired pathogens

Surbhi Malhotra, UA & José Cortiñas, UHasselt

15.00 – 15.30 Application of different statistical models to decide on the strategy for the diagnosis of M.

pneumoniae infections.

Katherine Loens, UA & Girma Minaluayele, Uhasselt

15.30 – 16.00 Coffee break

16.00 – 17.15 Session 5 – New frontiers in cell‐based therapy

Chair: Zwi Berneman & Paul Jansen

16.00 – 16.15 State of the art on innate immune responses

Zwi Berneman, UA

16.15 – 16.45 Towards understanding the brains innate immune responses: lessons from stem cell

transplantation in the central nervous system

Peter Ponsaerts, UA

16.45 – 17.15 Triggering innate immunity to improve cancer immunotherapy

Evelien Smits, UA & Eva Lion, UA

17.15 – 17.30 Concluding remarks

Ann Peters, UHasselt

17.30 Reception and buffet


85

10.4 ANNEX IV: Extracts of the Flemish Government Directive

HOOFDSTUK [Ibis.] - Financieringsbeginselen

B.Vl.R. 24-1-2003

Artikel [1bis.]

§ 1 Elk van de universiteiten, bedoeld in artikel 3 van het decreet van 12 juni 1991 betreffende de universiteiten in de Vlaamse Gemeenschap, brengt de financiële middelen die door de Vlaamse Gemeenschap overeenkomstig artikel 168 van het decreet worden bijgedragen voor wetenschappelijk onderzoek, onder in een intern bestemmingsfonds, genoemd "Bijzonder Onderzoeksfonds".

§ 2 Onder de term "de middelen van het Bijzonder Onderzoeksfonds" wordt in dit Besluit verstaan : de overheidsbijdragen bedoeld in artikel 2 van dit besluit, aangevuld met de eigen bijdrage, bedoeld in § 1 van artikel 6 van dit besluit.

§ 3 Ieder jaar voor 1 oktober deelt de Vlaamse regering aan elke universiteit het bedrag mede van de overheidsbijdragen die zij krachtens artikel 2 van dit besluit kunnen verwachten. De raming van de inkomsten en de uitgaven van het Bijzonder Onderzoeksfonds maakt integraal deel uit van de begroting van de universiteit onder de afdeling IV.

§ 4 De overheidsbijdragen aan het Bijzonder Onderzoeksfonds worden door de Vlaamse Regering definitief vastgesteld van zodra de algemene uitgavenbegroting van de Vlaamse Gemeenschap voor het desbetreffende begrotingsjaar is vastgelegd.

[Hoofdstuk IVbis. - De Methusalem-financiering voor internationaal toonaangevende onderzoekers

Afdeling 1. - Algemeen

Art. 14bis.

Voor het toekennen van langetermijnprogramma-financiering aan een beperkt aantal uitmuntende ZAP-leden, verbonden aan universiteiten in de Vlaamse Gemeenschap, wordt per universiteit een overheidsbijdrage, verder de Methusalem-financiering genoemd, toegekend.

De Methusalem-financiering wordt toegekend en aangewend overeenkomstig de voorwaarden gesteld in dit hoofdstuk.

Afdeling 2. - Kenmerken van de financiering

Art. 14ter.

§ 1. Voor het begrotingsjaar 2006 wordt de Methusalem-financiering vastgesteld op 3.000.000 euro. Dit bedrag geldt als referentiebedrag. Binnen de perken van de

- Annex IV -

86

begrotingskredieten wordt de subsidie geleidelijk verhoogd in de periode 2007-2010 om in 2010 haar hoogtepunt te bereiken.

§ 2. De Methusalem-financiering wordt jaarlijks geïndexeerd, conform artikel 2, § 2.

§ 3. De verdeling van de Methusalem-financiering over de Vlaamse universiteiten gebeurt overeenkomstig de in artikel 3 bedoelde verdeelsleutel.

§ 4. De Methusalem-financiering wordt met behoud van bestemming toegevoegd aan het Bijzonder Onderzoeksfonds.

De aan het Bijzonder Onderzoeksfonds toekomende middelen die na afloop van het betrokken kalenderjaar niet zijn toegewezen, kunnen met behoud van bestemming worden overgedragen naar de begroting van de universiteit.

§ 5. Het staat de universiteiten vrij het beschikbare bedrag voor de Methusalem-financiering te verhogen :

1° uit eigen middelen en/of

2° uit het onbestemde deel van het Bijzonder Onderzoeksfonds.

De in het eerste lid, 2°, bedoelde inbreng is vanaf 2010 beperkt tot maximaal 5% van het onbestemde deel van het Bijzonder Onderzoeksfonds.

Artikel 6, § 1, en artikel 8, 7° zijn niet van toepassing op de Methusalem-financiering.

§ 6. Voor de uitvoering van de Methusalem-financiering kunnen de universiteiten overheadkosten aanrekenen tot een maximum van 10 %.

[[De overheadkosten kunnen worden besteed aan de vergoeding van kosten (werkingskosten en loonkosten) die rechtstreeks verbonden zijn aan het beheer van de ten laste van de Methusalemmiddelen bekostigde onderzoeksprojecten, of aan de vergoeding van centrale beheerskosten en algemene exploitatiekosten van de universiteit.]]

Afdeling 3. - Voorwaarden voor de financiering

Art. 14quater.

§ 1. De Vlaamse universiteiten zijn belast met het operationeel en financieel beheer van de Methusalem-financiering.

§ 2. Elke universiteit legt de voorwaarden van de Methusalem-financiering in een reglement vast. Dit reglement werkt de nadere regelen uit met betrekking tot :

1° de organisatie van de oproep, als bedoeld in artikel 14quinquies ;

2° de eisen waaraan kandidaten moeten voldoen, als bedoeld in artikel 14sexies ;

3° de selectieprocedure, als bedoeld in artikel 14septies ;


87

4° de evaluatie, als bedoeld in artikel 14octies ;

5° de procedure voor beëindiging, als bedoeld in artikel 14novies.

Art. 14quinquies.

§ 1. De universiteit die de procedure start voor de toekenning van Methusalem-financiering door middel van het lanceren van een oproep, deelt dit aan de andere Vlaamse universiteiten mee in het kader van een mogelijk overleg inzake samenwerking tussen onderzoekers uit verschillende instellingen.

§ 2. Kandidaten-onderzoekers dienen hun aanvraag voor het bekomen van Methusalem-financiering in bij hun universiteitsbestuur.

In de aanvraag verklaren zij uitdrukkelijk in te stemmen met een eventuele bekendmaking conform artikel 14ter decies, § 2.

Art. 14sexies.

Kandidaten voor de Methusalem-financiering moeten :

1° aan de criteria van excellentie voldoen waaruit blijkt dat ze substantieel bijdragen aan de ontwikkeling van hun vakgebied en hiervoor internationale erkenning genieten;

2° bewijzen dat zij meer dan andere onderzoekers bestaande financieringskanalen, zoals GOA-, IUAP-, EU-, FWO- en IWT-financiering, hebben weten te benutten;

3° over een onderzoeksgroep beschikken met een voldoende kritische massa, zoals ondermeer kan blijken uit het aantal postdoctorale onderzoekers dat hiervan over een langere periode deel uitmaakt;

4° een onderzoeksplan bij de betreffende universiteit(en) indienen, dat een begroting bevat met een indicatieve verdeling van de geplande uitgaven over een periode van zeven jaar.

Art. 14septies.

§ 1. Voor de beoordeling van de kandidaten stelt elke universiteit internationale panels samen. De leden van deze panels zijn niet in België werkzaam en genieten een internationale erkenning. Bij de samenstelling van de panels wordt rekening gehouden met de discipline of, in geval van interdisciplinair onderzoek, met de disciplines waarin de kandidaten actief zijn. In een panel dient de universiteit er naar te streven dat ten hoogsten 2/3den van het totaal aantal leden behoren tot hetzelfde geslacht. In het geval van een samenwerkingsverband tussen twee of meer universiteiten, zoals bedoeld in § 7, stellen de betrokken universiteiten één enkel panel samen.

§ 2. Gemiddeld over alle panels, die een universiteit instelt, vanaf de inwerkingtreding van deze bepaling tot eind 2009, kan ten hoogste 2/3den van het totaal aantal leden tot hetzelfde geslacht behoren. Panels die door twee of meer universiteiten samen worden ingesteld, worden bij deze berekening aan elk van deze universiteiten toegewezen.

- Annex IV -

88

Indien een universiteit niet voldoet aan de in het eerste lid bedoelde regel, wordt voor het eerst vanaf 2011 de overheidsbijdrage aan het BOF verminderd met 0,25 % en dit tot het jaar t waarbij in het jaar (t-2) de instelling aan deze voorwaarde voldoet.

§ 3. De universiteit legt de samenstelling van de panels voor voorafgaand advies voor aan het FWO. Het FWO voert een meta-beoordeling van de internationale wetenschappelijke erkenning van de panelleden door en formuleert op grond daarvan een gemotiveerd advies. Indien het advies afwijzend is, geeft het FWO aan op welke wijze de vastgestelde gebreken geremedieerd kunnen worden. Slechts na positief advies van het FWO kan het panel worden ingesteld.

§ 4. Bij de beoordeling van een aanvraag past het panel de in artikel 14quater, § 2, 2°, bedoelde eisen toe, rekening houdend met de specificiteit van het betrokken vakgebied en onderzoeksdomein.

Het panel maakt de wijze van toetsing inzichtelijk.

Het panel gaat tevens na of met het aangevraagde bedrag van de Methusalem-financiering de onderzoeksgroep verder uitgebouwd kan worden tot een internationale referentiepositie. Het panel kan in dit verband bijsturingen voorstellen.

§ 5. Het panel legt zijn bevindingen neer in een omstandig geargumenteerd advies.

§ 6. Op advies van de onderzoeksraad en eventueel andere door het universiteitsbestuur aangeduide instanties beslist het universiteitsbestuur rekening houdend met het globale onderzoeksbeleid van de universiteit welke kandidaten die door een panel positief werden beoordeeld, financiering zullen ontvangen. Indien het aangevraagde bedrag aan financiering wordt aangepast dient het instellingsbestuur rekening te houden met het advies van het panel ter zake en zijn beslissing om hier eventueel van af te wijken te onderbouwen.

§ 7. Als twee of meer universiteiten beslissen samen financiering toe te kennen, sluiten ze een overeenkomst af, waarin het volgende bepaald wordt :

1° de getroffen regeling voor het functioneren van het geheel;

2° het aandeel van elke instelling in de financiering;

3° de modaliteiten inzake beëindiging van de financiering overeenkomstig artikel 14octies.

Afdeling 4. - Evaluatie

Art. 14octies.

§ 1. De onderzoeker die financiering ontvangt, wordt om de zeven jaar door een panel, dat aan de in artikel 14septies bedoelde voorwaarden voldoet, geëvalueerd.

Dit panel beoordeelt :

1° of het verrichte werk internationaal toonaangevend is en aan de verwachtingen voldoet;


89

2° het human resources beleid en in het bijzonder de mate waarin post-doctorale onderzoekers die werken in onderzoeksgroepen van ZAP-leden die Methusalem-financiering ontvangen, worden gestimuleerd ervaring op te doen met het opzetten van zelfstandig onderzoek;

3° of het onderzoeksplan voor de volgende zeven jaar en de aangevraagde financiering adequaat zijn.

Het panel kan suggesties voor de ontwikkeling van het onderzoek doen.

In het geval van een samenwerkingverband tussen twee of meer universiteiten, zoals bedoeld in artikel 14septies, § 7, wordt door de betrokken universiteiten één enkel evaluatiepanel samengesteld.

§ 2. Op basis van de in § 1 beschreven tussentijdse evaluatie beslist het universiteitsbestuur over de voortzetting van de financiering.

Afdeling 5. - Beëindiging van de financiering

Art. 14novies.

§ 1. Als de financiering wordt beëindigd op grond van een negatieve tussentijdse evaluatie, worden de toegekende middelen vanaf het jaar dat de beslissing is genomen, jaarlijks verminderd met 25 %.

Als de financiering wordt beëindigd omdat het ZAP-lid het emeritaat bereikt, worden de toegekende middelen [[vanaf het derde jaar]] voor de beëindiging jaarlijks verminderd met 25 %.

Indien een onderzoeker, die financiering ontvangt, om andere redenen dan het emeritaat de universiteit verlaat, duidt het instellingsbestuur een gewoon hoogleraar aan om tijdelijk als wetenschappelijk directeur op te treden en wordt de regeling betreffende de afbouw van de financiering, vermeld in het tweede lid, van toepassing.

§ 2. Als gevolg van de toepassing van de in § 1 beschreven geleidelijke beëindiging, wordt een nieuwe financiering stapsgewijs opgebouwd. Met de vrijgekomen middelen kan vervolgens een nieuwe kandidaat voor de Methusalem-financiering geselecteerd worden.

§ 3. Het bereiken van het emeritaat houdt niet in dat de betrokken universiteit de financiering niet aan een andere onderzoeker kan toekennen, op voorwaarde dat conform artikel 14septies blijkt dat deze aan de in artikel 14sexies vermelde criteria voldoet.

Afdeling 6. - Organisatorische elementen

Art. 14decies.

§ 1. Het ZAP-lid ontvangt, behoudens in het geval van artikel 14novies, § 1, financiering tot aan het emeritaat. Het ZAP-lid treedt op als wetenschappelijk directeur en draagt de eindverantwoordelijkheid voor de besteding van de onderzoeksmiddelen, het onderzoeksbeleid en het dagelijks bestuur van de onderzoeksgroep.

- Annex IV -

90

Bij een samenwerkingsverband tussen twee of meer universiteiten fungeert het ene ZAP-lid als directeur en de andere(n) als codirecteur(s).

§ 2. De omvang van de middelen is afhankelijk van de discipline en bedraagt over de periode van zeven jaar jaarlijks gemiddeld minstens viermaal het bedrag als bedoeld in artikel 8, eerste lid, 2, en maximaal 2.000.000 euro per jaar.

In het geval van een samenwerkingsverband tussen twee of meer universiteiten, zoals bedoeld in artikel 14septies, § 7, gelden bovenstaande minimum- en maximumbedragen voor de financiering die de universiteiten samen toekennen.

§ 3. Het ZAP-lid kan de middelen besteden aan werking, personeel, uitgezonderd de salariskosten bedoeld in § 5, en uitrusting.

§ 4. De universiteit stelt aan het ZAP-lid en zijn/haar onderzoeksgroep de nodige lokalen en basisvoorzieningen ter beschikking.

§ 5. De universiteit betaalt de salariskosten van het ZAP-lid en eventuele andere aan de onderzoeksgroep verbonden ZAP-leden.

Art. 14undecies.

Het toekennen van een Methusalem-financiering aan ZAP-leden sluit niet uit dat onderzoekers die verbonden zijn aan de onderzoeksgroep van betrokken ZAP-leden middelen verwerven van andere financieringsbronnen, in het bijzonder de middelen vermeld in artikel 1bis.

Art. 14duodecies.

§ 1. In de schoot van de onderzoeksgroep van het ZAP-lid waaraan een Methusalem-financiering wordt toegekend, wordt een beheerscomité ingesteld. Hierin zetelen minstens de ZAP-leden die verbonden zijn aan de onderzoeksgroep. Het ZAP-lid waaraan de financiering wordt toegekend, fungeert als voorzitter. In het geval van een samenwerkingsverband tussen twee of meer universiteiten, zoals bedoeld in artikel 14septies, § 7, wordt één enkel beheerscomité ingesteld. Eén van de ZAP-leden waaraan financiering wordt toegekend, fungeert als voorzitter en de/het andere ZAP-lid/leden waaraan financiering wordt toegekend als co-voorzitter.

§ 2. Het beheerscomité staat in voor het bestuur van de onderzoeksgroep(en), inzonderheid voor het uitstippelen van het wetenschappelijk beleid van de onderzoeksgroep(en).

§ 3. De onderzoeksgroep of, in geval van een samenwerkingsverband, de onderzoeksgroepen, stelt/stellen eveneens een adviesraad in, waarin onderzoekers die in het betrokken vakgebied internationale erkenning genieten zetelen. Deze adviesraad geeft onder meer ondersteuning bij het uitstippelen van het langetermijnonderzoeksbeleid en het vaststellen van prioriteiten in de onderzoeksagenda.

Afdeling 7. - Rapportering

Art. 14ter decies.


91

§ 1. Artikel 12, § 1, § 2 en § 3 is van toepassing op de Methusalem-financiering.

Het jaarverslag bevat voor wat betreft de Methusalem-financiering minstens :

1° een overzicht van de gefinancierde initiatieven;

2° een toetsing van de stand van uitvoering van de gefinancierde initiatieven;

3° de eventuele bijsturing van de gefinancierde initiatieven.

§ 2. Het universiteitsbestuur publiceert op haar website de gemotiveerde beslissing van het universiteitsbestuur, bedoeld in artikel 14septies, § 7, ten aanzien van de geselecteerde kandidaat.

Tevens worden de beslissingen over de voortzetting van de financiering, bedoeld in artikel 14octies, § 2, gepubliceerd op de website van de universiteit.

In geval van een samenwerkingsovereenkomst wordt deze eveneens op de website van de betrokken universiteiten gepubliceerd. Ter zake kunnen de universiteiten beslissen om een gemeenschappelijke website te gebruiken.

Art. 14quater decies.

Om het verloop van de Methusalem-financiering systematisch te volgen, zullen de universiteiten jaarlijks aan de Minister, bevoegd voor het wetenschappelijk onderzoek en het technologisch innovatiebeleid, rapporteren over de volgende set van statistische parameters :

1° de verhouding tussen het aantal ingediende en gehonoreerde aanvragen (in aantal en in budget, wetenschapsgebied, nationaliteit (Belgisch, EU, niet-EU) en geslacht;

2° de verhouding tussen de aangevraagde en de toegekende kredieten bij geselecteerde voorstellen.]

B.Vl.R. 8-12-2006; [[ ]] B.Vl.R. 12-12-2008

- Annex IV -

92


93

10.5 ANNEX V: Personnel list anno 2009 Nr Naam Label Level FTE Affiliation

1 Adriaenssens,Niels BAP predoc 1,00 LMM 2 Aerts Marc (head) ZAP gewoon hoogleraar 1,00 CenStat 3 Alonso Abad Ariel BAP postdoc 1,00 CenStat 4 Amadeo,Brice NA predoc NA LMM 5 Anguille,Sébastien BAP predoc 1,00 LEH 6 Anthierens,Sibyl BAP postdoc nav 0,80 LMM 7 Bergwerf,Irene BAP predoc 1,00 LEH 8 Berneman,Zwi ZAP gew.hoogl. 1,00 LEH 9 Beutels,Philippe ZAPBOF hfd.docent 1,00 CEV

10 Bilcke,Joke BAP predoc 0,90 CEV 11 Bontenakel,Aline ATP technician 1,00 CEV 12 Braeckman,Tessa BAP predoc 1,00 CEV 13 Broodhaers,Serge ATP technician 1,00 CEV 14 Bruckers Liesbeth BAP predoc 1,00 CenStat 15 Bruynseels,An ATP technician 0,75 CEV 16 Bryssinck,Liesbeth ATP technician 1,00 LMM 17 Burzykowski Tomasz ZAP hoofddocent 0,70 CenStat 18 Callaert Kris ATP admin 0,70 CenStat 19 Castro Sanchez Yovanna BAP predoc 1,00 CenStat 20 Chapelle,Sabine ATP technician 0,50 LMM 21 Claesen Jurgen BAP predoc 1,00 CenStat 22 Coenen,Samuel BAP onz.leider 1,00 LMM 23 Cools,Nathalie BAP postdoc FWO 1,00 LEH 24 Cortiñas Abrahantes José BAP postdoc 1,00 CenStat 25 Creemers An AAP predoc 1,00 CenStat 26 Daans,Jasmijn ATP technician 0,80 LEH 27 Del Fava Emanuele BAP predoc 1,00 CenStat 28 De Vos Beatrice NA predoc NA CEV 29 Desloovere,Hilde ATP admin 1,00 CEV 30 Dighou,Naïma ATP admin 1,00 CEV 31 Drapier Nico Consultant consultant 1,00 LMM 32 Engelen,Emmy ATP admin 1,00 CEV 33 Faes Christel ZAP docent 1,00 CenStat 34 Gaddah Auguste BAP predoc 1,00 CenStat 35 Gadisseur,Alain BAP gastprof 1,00 LEH 36 Gazin,Muriel BAP predoc 1,00 LMM 37 Geerdens Candida AAP predoc 1,00 CenStat 38 Gitome Arthur BAP predoc 1,00 CenStat 39 Goeyvaerts Nele BAP predoc 1,00 CenStat 40 Goossens,Herman ZAP gew.hoogl. 1,00 LMM 41 Grouwels Yves BAP predoc 1,00 CenStat 42 Habteab Ghebretinsae Aklilu BAP predoc 1,00 CenStat 43 Haldermans Philippe AAP predoc 1,00 CenStat 44 Hendrickx,Greet ATP admin 1,00 CEV 45 Hens Niel BAP docent‐gastprof 0,50‐0,50 CenStat‐CEV 46 Hens,Annick BAP predoc 1,00 CEV 47 Ieven,Margareta ZAP hfd.docent 0,10 LMM 48 Kafeja,Froukje BAP predoc 0,90 CEV 49 Kasim Adetayo BAP predoc 1,00 CenStat

- Annex V -

94

50 Khamiakova Tatsiana BAP predoc 1,00 CenStat 51 Laenen Annouschka BAP postdoc 1,00 CenStat 52 Lammens,Christine ATP technician 1,00 LMM 53 Lejeune,Olivier BAP postdoc nav 1,00 CEV 54 Lenders,Kevin ATP technician 1,00 LEH 55 Leten,Gert ATP technician 1,00 LMM 56 Leuridan,Elke AAP predoc 1,00 CEV 57 Lin Dan BAP postdoc 1,00 CenStat 58 Lion,Eva BAP predoc 1,00 LEH 59 Litiere Saskia BAP postdoc 1,00 CenStat 60 Loens,Katherine BAP postdoc nav 0,80 LMM 61 Luyten,Jeroen BAP predoc 1,00 CEV 62 Malhotra,Surbhi BAP postdoc FWO 1,00 LMM 63 Marais,Christiaan BAP predoc 1,00 CEV 64 Martin,Manuella BAP lesgever 1,00 LMM 65 McNeil Pamela NA predoc NA LMM 66 Mertens,Gerhard BAP vrijw.med 1,00 LMM 67 Michiels Barbara BAP predoc 0,25 Huisartsgen 68 Milanzi Elasma BAP predoc 1,00 CenStat 69 Minalu Ayele Girma BAP predoc 1,00 CenStat 70 Molenberghs Geert ZAP gewoon hoogleraar 0,70 CenStat 71 Muller,Arno BAP postdoc.sub 1,00 LMM 72 Muylle,Ludo BAP gastprof 0,25 LEH 73 Neyens Thomas BAP predoc 1,00 CenStat 74 Nijs Griet ATP technician 1,00 LEH 75 Njagi Edmund BAP predoc 1,00 CenStat 76 Nuyts,Amber BAP predoc 1,00 LEH 77 Nys,Sophie ATP admin 0,80 LMM 78 Nysen Ruth AAP predoc 1,00 CenStat 79 Panis,Thomas BAP predoc 1,00 CEV 80 Ponsaerts,Peter BAP postdoc FWO 1,00 LEH 81 Pramana Setia BAP predoc 1,00 CenStat 82 Prenen Leen AAP predoc 1,00 CenStat 83 Quisquater Charlotte ATP technician 1,00 LEH 84 Reekmans,Kristien BAP predoc 1,00 LEH 85 Sabiiti Wilber BAP predoc 1,00 LMM 86 Schroyens,Wilfried ZAP hfd.docent 0,10 LEH 87 Shkedy Ziv ZAP docent 1,00 CenStat 88 Smits,Evelien BAP postdoc nav 1,00 LEH 89 Sotto Cristina AAP postdoc 1,00 CenStat 90 Stein Barbara ATP technician 1,00 LEH 91 Stroobants Rudi Consultant consultant 0,50 LMM 92 Struyven,Anne ATP admin 1,00 LMM 93 Suykens,Leen BAP predoc 1,00 CEV 94 Tack,Sue ATP admin 0,60 CEV 95 Tambuyzer,Bart BAP postdoc 1,00 LEH 96 Teshome Ayele Birhanu BAP predoc 1,00 CenStat 97 Theeten,Heidi AAP predoc 1,00 CEV 98 Thijs Herbert BAP postdoc 1,00 CenStat 99 Vael,Carl BAP vrijw.med 1,00 LMM 100 Van Bockstaele,Dirk R BAP gastprof 1,00 LEH 101 Van Camp,Kirsten ATP technician 1,00 LEH


95

102 Van Damme,Pierre ZAP hoogleraar 1,00 CEV 103 Van de Velde,Ann BAP lesgever 1,00 LEH 104 Van Der Planken,Marc BAP lesgever 1,00 LEH 105 Van Driessche Ann BAP predoc 1,00 LEH 106 Van Heirstraeten,Liesbet BAP predoc 1,00 LMM 107 Van Herck Koen ZAP docent 0,10 CEV 108 Van kerckhoven,Margaretha ATP admin 0,70 LMM 109 Van Tendeloo,Vigor ZAPBOF docent 1,00 LEH 110 Van Winckel,Anna ATP technician 1,00 CEV 111 Vanderstraeten,Anouk ATP technician 1,00 LMM 112 Vanhommerig,Evelyn AAP predoc 1,00 LMM 113 Vankerckhoven,Vanessa BAP postdoc nav 1,00 CEV 114 Vercauteren,Greetje ATP technician 1,00 LMM 115 Vermeulen,Katrien BAP postdoc nav 1,00 LEH 116 Vervoort,Jascha BAP predoc 1,00 LMM 117 Verwimp Gino ATP admin 1,00 CEV 118 Vorsters,Alex ATP technician 1,00 CEV 119 Wijdooghe,Monique ATP technician 0,52 LMM 120 Zarb Peter Consultant consultant 0,50 LMM 121 Zhu Qi BAP predoc 1,00 CenStat

Documents

Methusalem Report 2008 2009 - Universiteit Hasselt · 2011. 5. 19. · - Methusalem Report 2008-2009 - 9 HASSELT UNIVERSITY Methusalem Team leader: Prof. Dr. Geert Molenberghs Research